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Abstract
Hemodialysis (HD) provides life-saving treatment in individuals with kidney failure.
However, HD is associated with poor quality of life and extremely high mortality rates mainly
caused by cardiovascular disease due to heart failure and sudden cardiac death. Standard
pharmacological treatment developed within the non-kidney disease community are largely
ineffective in HD patients because of the difference in pathophysiology of cardiovascular
mortality. HD treatment causes hypotension and recurrent ischemic injury to multiple vascular
beds including the heart, leading to heart failure. These injuries can be abrogated by improving the
patient’s tolerability of the treatment. To apply interventions that may improve hemodynamic
tolerability of HD, it is crucial to understand the mechanisms of HD-induced injury at every layer
of the vasculature: the endothelial, microvasculature and macrovasculature. The purpose of this
thesis was to study the endothelial and vascular dysfunction affecting tissue perfusion as a result
of HD and under conditions of intradialytic exercise and alteration of dialysate sodium
concentration.
In one study, computed tomography (CT) imaging and echocardiography was used to
identify the presence of coronary artery disease (CAD), quantify myocardial perfusion, and
determine myocardial segments with stunning. HD induced myocardial ischemia and stunning in
all participants independent of CAD. However, individuals with CAD demonstrated reduction in
segmental myocardial perfusion which corresponded to an increased number of myocardial
segments experiencing stunning compared to HD participants without CAD. The findings from
this study suggest that the addition of CAD is associated with reduced tolerance to HD, even if the
CAD is not clinically evident.
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The second study in this thesis investigated the role of dialysate sodium as a contributor to
HD-induced endothelial injury, predisposing HD patients to microvascular dysfunction and
ischemia. The choice of dialysate sodium concentration is a difficult but crucial decision for the
care of HD patients. High sodium dialysate is prescribed to prevent intradialytic hypotension but
it is associated with high ultrafiltration, excess sodium deposition in the tissue, and injury to the
endothelial glycocalyx. In this study, sodium concentration was manipulated in a rat HD model to
study its effect on the endothelium as measured by plasma syndecan-1, and intravital video
microscopy to quantify microvascular perfusion. The findings of this study suggest high sodium
dialysate induced endothelial injury leading to functional changes in perfusion. Hence, a low
dialysate sodium prescription could be beneficial if the patient demonstrates hemodynamic
stability during HD.
In a third study, the mechanism and effects of intradialytic exercise was investigated using
CT perfusion imaging for quantification of myocardial perfusion and echocardiography to assess
myocardial stunning. In contrast to the hypothesis made by other investigators, intradialytic
exercise did not increase perfusion in the muscle. However, HD participants demonstrated a
decrease in myocardial stunning with exercise. These results suggest that intradialytic exercise is
not driven by perfusion-related mechanisms but rather by means of cardioprotection to improve
ischemic

tolerability

of

the

tissue

in

the

HD

setting

of

challenged

perfusion.
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Lay Summary
Kidney failure is common, and it is the inability for the kidneys to clean the blood in our
body from waste and toxins. The build-up of waste products can be very dangerous, and it must
be removed regularly by a machine (hemodialysis, HD) that acts as an artificial kidney. HD is a
life-saving therapy but people who need it die much more often than people with healthy kidneys.
The most common cause of death in patients on HD is heart failure. This is because HD requires
removal of blood from your body into a circuit that is outside of your body, causing the blood flow
in the small blood vessels in the heart tissues to fall. Low blood flow means not enough oxygen
will be delivered to the tissue causing it to fail. The purpose of this thesis was to study the changes
in the blood vessels effecting blood flow in the tissue due to HD and under conditions of exercise
and alteration in sodium levels of the dialysis fluid.
In one study, blood flow in the heart tissue and the contractile function of the heart during
HD was studied in patient with large vessel disease using computed tomography (CT) imaging
and a heart ultrasound. HD affected blood flow in all patients, whether or not they had large vessel
disease. Compared to HD patients without large vessel disease, individuals with large vessel
disease had even lower blood flow to certain tissue regions of the heart during HD that
corresponded to the loss in contractility of the heart. Therefore, large vessel disease added to the
injury that HD patients experienced during HD treatment.
In a second study, a rat HD model was used to study the role of sodium in the small vessels
and its circulation. The purpose of this study was to determine the optimal sodium level for the
dialysate fluid which helps the patient’s tolerate HD treatment better. The results showed that high
levels sodium in the blood caused damage to the walls of the blood vessels that reduced the
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effectiveness of the vessel from circulating blood in the tissue. This study concluded that dialysis
fluid with low sodium would cause less damage to the blood vessel wall and reduce the risk of low
blood flow during HD.
In a third study, exercise during HD treatment was evaluated in human participants to
study its effect on blood flow and overall heart function. In this study, we showed that exercise did
not change blood flow in the heart tissue, but it improved heart contractility. It was concluded that
exercise is able to protect the heart from low blood flow and starvation of oxygen that is
experienced during HD.
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Chapter 1

1 Introduction
Parts of this chapter has been published in Current Opinions in Nephrology and Hypertension:
this is a non-final version of an article published in final form in Current Opinions in Nephrology
and Hypertension 29 (6), 555-563. November 2020., Authored by Lisa Hur and Christopher W.
McIntyre, titled “Current and novel imaging techniques to evaluate myocardial dysfunction during
hemodialysis.”

1.1 Overview of Thesis
The purpose of this thesis was to study the endothelial and microcirculatory dysfunction
effecting tissue perfusion as a consequence of hemodialysis (HD) and under conditions of
intradialytic exercise and alteration of dialysate sodium. The studies presented in this thesis applied
techniques such as echocardiography, dynamic contrast enhanced computed tomography (CT),
coronary CT angiography, intravital microscopy, and enzyme-linked immunosorbent assay
(ELISA) to study the endothelial, microvascular, macrovascular, and functional changes in both
human HD participants and pre-clinical rodents during HD.
Section 1.2.1-1.2.2 of this chapter provides a brief summary of the anatomy, function and
pathophysiology surrounding the kidney and it related-disease forms. Section 1.2.3-1.2.4
summarized the available treatment methods for end stage renal disease and its associated
complications. The remaining sections (Sections 1.3-1.5) address the techniques that have been
used to assess HD-induced injury and detail the techniques that were utilized in this thesis.
The completed scientific investigations are described in the following three chapters.
Chapter 2 investigates the association between the vascular bed of the heart (myocardial perfusion)
and the health of the coronary arteries (macrovasculature) supplying the blood in response to HD.
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It was hypothesized that the impairment of the coronary arteries would exasperate the ischemic
injury associated with HD as measured by dynamic myocardial CT perfusion and significantly
reduce cardiac function as assessed with echocardiography. In line with this hypothesis,
myocardial segments with hemodynamically significant stenoses were less perfused and
participants with this impairment experienced higher levels of myocardial stunning with HD.
In Chapter 3 of this thesis, intravital microscopy was utilized in a preclinical platform to
examine the endothelial and microvascular response to levels of dialysate sodium during HD. It
was hypothesized that levels of acute sodium loading during HD results in direct endothelial cell
injury marked by increased plasma syndencan-1, and a decrease in microvascular perfusion.
With the interest of minimizing the adverse effects of HD, an intradialytic imaging study
was performed (Chapter 4) to examine intradialytic exercise as a way of mitigating the HD-induced
ischemic injury. The effects of intradialytic exercise were assessed by quantification of plasma
syndecan-1, global myocardial perfusion, and segmental myocardial stunning.
The last chapter of this thesis (Chapter 5) summarizes the scientific contributions of these
works and details opportunities for future investigations.

1.2 The Kidneys
1.2.1 Kidney Anatomy and Function
The kidneys are part of the renal system, and its principle function is the production of
urine which is composed of water, metabolic by-products, and ions1. From this, we know that it
plays a major role in the regulation of water and electrolyte balance, the excretion of waste
products, the absorption and secretion of bicarbonate and hydrogen ions, as well as the secretion
of essential hormones involved in the regulation of physiological functions2,3.
2

The kidneys are located in the dorsal abdomen and each kidney has an adrenal gland on its
upper surface responsible for the production of hormones. Each kidney is composed of three
layers: the renal capsule of collagen fibers (innermost layer), the perirenal fat capsule (a layer of
adipose tissue), and the renal fascia outermost later of collagen fibers1–3. These three layers
together provides each kidney structural stability 1–3. Within the cross section of the kidney (Figure
1-1), the outermost region is referred to as the renal cortex and inner layer, the renal medulla 1–3.
The renal medulla can be separated into two distinct regions: the renal pyramids and the renal
columns that separate the renal pyramids 1–3. Nearing the center of the kidey, each renal pyramid
opens into the minor calyces (singular: minor calyx) which mergers together at the core of the
kidney to form the major calyx that leads into the renal pelvis 1–3.

Figure 1-1 Anatomy of the kidney and nephron
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The nephron is known to be the basic functional unit of the kidney, populating at one
million per kidney. The nephron consists of two distinct parts: the renal corpuscle and the renal
tubule. The renal corpuscle is composed of the glomerulus (a bundle of capillaries) and the
Bowman’s capsule (site of storage for the glomerular filtrate). First, the blood flows into the kidney
through the renal artery that branch into smaller vessels, entering a glomerulus where filtration
takes places through an afferent arteriole1. The amount of glomerular filtrate produced is
dependent on the percentage of the body’s cardiac output being delivered to the kidneys, roughly
twenty to twenty-five percent. Everyday approximately 180 liters (or 125 mL per minute) of filtrate
is produced by the glomerulus4–6. The rate at which the glomerulus filters the blood is referred to
as the glomerular filtration rate (GFR, mL/min/1.73m2), and it is determined by the filtration
pressure gradient between the glomerulus and the Bowman’s capsule and can be modified by the
contraction and relaxation of the smooth muscles surrounding the afferent and efferent arterioles4–
6

. The volume of filtrate produced during this process are stored in the Bowman’s capsule before

making its way into the renal tubule while the filtered blood returns to the systemic circulation
through the efferent arterioles7. Within the renal tubule, the glomerular filtrate will undergo further
modifications via tubular reabsorption and secretion within the compartments of the renal tubule
for the production of urine.

1.2.2 Renal Pathophysiology
1.2.2.1

Acute Kidney Injury

Acute kidney injury (AKI) is the sudden loss of kidney function defined by a decrease in
urine output (less than 0.5ml/kg/hr within 6 - 12 hours) and/or a rapid increase in serum creatinine
(greater than 1.5-fold from baseline over 10 days; greater than 26.4µmol/L in 48 hours)8. In the
early 20th century, the term acute renal failure was used to characterize the compounding effects
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of abrupt decrease in urine output and the accumulation of uraemic toxins8. This terminology was
re-examined and replaced by the standardized terminology AKI, that is associated with the RIFLE
(Risk, Injury, Failure, Loss and End-stage kidney disease) classification system to grade the
severity of the injury8. The RIFLE classification system is dependent on serum creatinine and urine
output and was adopted into the KDIGO (Kidney Disease Improving Global Outcomes) guidelines
to ensure international coherence of research.
Approximately 10 - 15% of hospitalization involve complications of AKI, making up more
than 50% of the intensive care unit9. The diagnosis and treatment of AKI is complicated due to the
presentation of multiple underlying causes including sepsis, ischemia, and nephrotoxicity. The
etiology of AKI can be divided into three major categories: pre-renal, intra-renal, and post-renal10.
Pre-renal causes of AKI result from impairment in renal perfusion, ultimately decreasing the GFR
without further damage to the renal parenchyma; possible abnormalities include hypovolemia,
impaired cardiac function, systemic vasodilation, and increased vascular resistance11. Intrinsic
AKI results from damage to parts of the kidney itself, for example, damage to the tubular,
glomerular, interstitial and the intra-renal vasculature. Lastly, post-renal AKI results from an acute
obstruction in the extrarenal and intrarenal space that impedes urinary flow8,9.
Urine and blood samples have been used to detect biomarkers of AKI including tissue
inhibitor of metalloproteinase-2, neutrophil gelatinase associated lipocalin, and cystatin C10. Upon
clinical presentation and diagnosis, AKI injuries are managed pharmacologically or through the
initiation of renal replacement therapy in the form of dialysis depending on the severity of the
injury.
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1.2.2.2

Chronic Kidney Disease

Chronic kidney disease (CKD) is an umbrella term encompassing any renal disease
resulting in the progressive loss of kidney function over time and is characterized by a reduction
in estimated GFR (eGFR) of less than 60 mL/min/1.73m2 12,13. In the recent years, the prevalence
of CKD has been rising worldwide; amounting to more than ten percent of the worldwide
population or over 850 million people14–16. CKD is most common in females (11.8%)16, in
individuals over 70 years of age (27.9%)16, and in ethnic minority groups17. CKD can be
categorized into five stages of severity depending on the eGFR and is summarized in Table 1-1.
Table 1-1 Stages of chronic kidney disease
Stage of CKD

eGFR (mL/min/1.73m2)

1
2
3a/b
4
5

³ 90
60 – 89
30 - 59
15 -29
< 15

Classification
Impairment
Normal
Mild
Moderate
Severe
Kidney Failure

of

Renal

The primary causes of CKD are diabetes (diabetic nephropathy)18–21 and hypertension
(hypertensive nephrosclerosis)21–23, and these factors contribute to increased risk for
cardiovascular (CV) morbidity and mortality in this population. According to the United States
Renal Data System’s 2020 report, over thirty-five percent of individuals diagnosed with CKD are
diabetic17. Diabetes mellitus is characterized by hyperglycemia resulting from defective insulin
action and secretion. Chronic hyperglycemia increases the deposition of extracellular matrix
protein which induces the expansion of the mesangium. At this time, the glomerular basement
membrane that assists with the filtration of waste and fluid from the blood thickens alongside the
development of glomerulosclerosis. These changes that occur in the glomeruli as a result of
6

hyperglycemia cause disturbances in the glomerular filtration rate, reducing kidney function as a
consequence of diabetes. Clinical trials investigating preventative measures of diabetic induced
kidney injury demonstrated that the practice of intensive blood glucose control early in the course
of the disease may delay or even prevent the progression of renal damage24.
Worldwide, hypertension is the strongest risk factor for cardiovascular disease (CVD) and
its association with CKD is well recognized25. The role of hypertension in renal disease is
complicated because it can be both a cause and a consequence, creating a vicious cycle that
ultimately exacerbates high blood pressure (BP) in CKD population. Mechanism of systemic
hypertension in this population include volume overload, salt retention, changes in BP regulating
hormones, overactive sympathetic nervous system, and endothelial dysfunction22,23. To manage
hypertension in CKD appropriately, acquisition of BP measurements and quantification of
proteinuria are key. Based on these measurements, hypertension can be managed through
pharmacological (antihypertensive medication) and non-pharmacological (such as reducing
dietary sodium intake and weight loss) treatment methods23.
Generally, CKD remains silent, and its symptoms are not evident until substantial decline
in kidney function. Prior to irreversible kidney failure, CKD can be diagnosed through routine
blood work and urinalysis. In advanced kidney disease, common symptoms include chest pain,
itchiness, loss of energy, irregular urination, muscle cramps, loss of appetite and shortness of
breath. With time, the kidney will gradually lose its ability to function and reach stage 5 of CKD
(kidney failure), requiring renal replacement therapy (RRT) to remove waste and fluid.
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1.2.2.3

End Stage Renal Disease

In 2010, approximately 2.6 million individuals worldwide were newly registered as having
treated end stage renal disease (ESRD) amounting to 4.9 – 9.7 million people with prevalent ESRD
that required treatment; an estimated 2.3 million or more people died prior to treatment initiation
due to the lack of access26. ESRD is the final stage of CKD where the kidney will no longer
function to rid toxins and waste from the body and is clinically defined by a GFR of less than
15mL/min/1.73m2. The two main causes of ESRD are diabetes and hypertension leading to
glomerulonephritis (inflammation of the glomerulus)22,23. One of the common characteristics of
rapidly progressing kidney injury from early stages of CKD to ESRD is the worsening of uremia27.
Uremia is the elevation in concentration of urea in the blood that is associated with electrolyte,
fluid, and hormonal imbalance experienced with a decline in kidney function28. In patients with
ESRD prior to RRT, urea levels in the blood are typically ten times greater than in healthy
individuals. In the past, urea was considered an inert molecule with no evidence of toxic effects.
However, in recent years, urea has been shown to interact and interfere with many biochemical
pathways (including the generation of cyanate and ammonia) and modulate organ function 29–31.
Uremia can be asymptomatic or symptomatic, nevertheless in conjunction with decline in kidney
function it may be an indication for the initiation of RRT to reverse uremic symptoms and prolong
life. With ESRD, the health of the kidney cannot be reversed.

1.2.3 Renal Replacement Therapy in ESRD
There are many clinical approaches to RRT, all of which have the common objective to
replace the function of a failed kidney and remove waste and toxin from the blood32,33. The point
at which to start RRT is a topic of debate. Observational studies have shown that early initiation
or preemptive interventions does not improve survival34–36. Generally, more than half of the ESRD
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patient population begin RRT when eGFR reaches a threshold of 10mL/min/1.73m2. If RRT is
initiated too late, the patients are at risk for complications of uremia, reduced quality of life, and
increased mortality rate. The decision to start RRT is not simply made on a single objective
measurement but is rather based on a combination of symptoms, biochemistry, fluid overload,
eGFR and most importantly, the patient’s preference. Modes of RRT include kidney transplant,
peritoneal dialysis, and hemodialysis (HD). In principle, the patients must only consider one
question to decide which form of RRT to receive: will transplantation improve my quality of life
compared to peritoneal dialysis or HD? To most patients and their kidney care team, the answer is
glaringly apparent because certain treatment methods are not available or unaffordable. The
upcoming sections 1.2.3.1 -1.2.3.3 aims to detail the different modes of RRT and the associated
risks and benefits.

1.2.3.1

Kidney Transplantation

When successful, kidney transplant remains the most favorable treatment option for ESRD
as it is associated with fewer complications and reduced mortality rates, while significantly
improving the quality of life33. Kidney transplantation as a potential method of treatment is widely
dependent on the availability of organs for transplantation, existing comorbid conditions of the
patient and their commitment to lifelong need for immunosuppressant drugs. Often, the general
public’s understanding of transplantation is an immediate cure. However, it involves regular
follow-up and continuous effort from the patient and the family to adhere to the medication
protocols37. With successful transplantation, the life-expectancy of a transplanted patient is still
much shorter than age- and sex-matched individuals with normal kidney function38. An additional
risk factor that transplanted patients face is the maintenance of the graft; the graft is lost prior to
death in more than half of the population with kidney transplant. When a graft is deemed lost or
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failed after a transplant, the recipient undergoes a re-transplantation procedure, or proceeds to
dialysis treatment. Long term survival of a graft depends on a multitude of factors including the
donor and recipient’s age, the type of immunosuppressant medication, the frequency of acute
rejection episodes, living versus deceased donor, and the delayed functionality of the graft39–43.
However, studies indicate superior outcomes with kidney transplantation compared with
peritoneal dialysis and HD treatment methods.

1.2.3.2

Peritoneal Dialysis

Peritoneal dialysis is one of the alternative modes of RRT and it is a process at which
solutes, fluids, and waste products are removed within the patient’s peritoneal cavity44–48. A
suitable healthy peritoneum is required to pursue this form of dialysis; contraindications include
adhesions, fibrosis, or malignancy in the peritoneum. For the performance of peritoneal dialysis, a
catheter is surgically inserted into the abdomen enabling the transfer of fluid in and out of the
abdominal cavity. The dialysis fluid, composed of varying levels of electrolyte and salt
concentration, precisely formulated to manage the solute composition in the plasma is connected
to the catheter to allow inflow of the dialysate into the peritoneal cavity. The exchange of solutes,
toxins, and fluids takes place across the peritoneal barrier between the dialysate fluid and the blood
within the peritoneal capillaries. The peritoneum itself is densely lined with the capillary-rich wall
and the efficiency at the which the solutes are cleared is dependent on multiple factors including
the permeability of the peritoneal barrier, the blood flow and vascularity within the capillary walls,
the surface area of the peritoneum, and osmotic or oncotic gradient generated through the instilled
dialysate content. Once, the waste products are filtered, it is drained out of the body into an empty
bag for disposal.
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Peritoneal dialysis can be delivered in two forms: continuous ambulatory peritoneal
dialysis and automated peritoneal dialysis. With continuous ambulatory peritoneal dialysis,
patients manually perform exchanges three to five times per day ranging at 1.5 to 3L per
exchange49. The automated peritoneal dialysis takes place at night while the patient sleeps. With
this form of peritoneal dialysis, the patient is hooked up to a machine that runs through the night
and a series of overnight exchanges are carried out automatically for 7 to 10 hours49. Peritoneal
dialysis is the favorable form of dialysis treatment allowing independence and flexibility for the
patient. It is often the method of choice for infants and children, in patients with difficult vascular
access for HD and in those who are active and working.

1.2.3.3

Hemodialysis

In the United States, over 500 000 ESRD patients were on HD as their primary mode of
RRT in 2019, of which approximate 492 000 individuals receive treatment in-center17. Patients on
HD require short daily treatments, typically thrice weekly for 3 to 5 hours per session or long
nocturnal treatment every other night for 8 to 10 hours per session50,51. Regardless of the type of
HD treatment, all patients require a well-functioning, durable vascular access for the performance
of the treatment. The three major types of vascular access are: primary arteriovenous (AV) fistulas,
synthetic arteriovenous fistulas (AV graft), and a central venous catheter (Figure 1-2) 52,53. Due to
its longevity and fewer probable complications, the AV fistula is the preferred vascular access for
HD.
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Figure 1-2 Types of hemodialysis vascular access. Recreated from Challenges and novel
therapies for vascular access in haemodialysis by Lawson, Niklason and Roy-Chaudhury, 2020.
At the start of HD treatment, the two dialysis lines are connected to the vascular access of
the patient; the arterial line allows the flow of blood from the body to the dialysis machine and the
venous line allows the filtered blood to return from the dialysis machine to the body (Figure 1-3)
54

. To prevent coagulation of blood within the extracorporeal circuit, heparin is infused into the

dialysis line. The exchange of water molecules, electrolytes and toxins occur once the blood
reaches the dialyzer, through a semi-permeable membrane. On the opposing sides of the
membrane, there is countercurrent flow of blood and dialysate fluid allowing the equilibrium of
solute concentration to be reached as solutes of specific size and charge pass through the semipermeable membrane. HD employs two processes for solute and fluid clearance: diffusive and
convective33. Diffusive clearance involves the movement of solutes down a concentration gradient,
from region of high concentration to low concentration and is most effective in the movement of
small solutes. Water molecules “follow” the solutes and its exchange is facilitated by the osmotic
gradient. Convective clearance, also known as ultrafiltration, is the most effective way of removing
fluid, utilizing the difference in transmembrane pressure to forcibly push water through the
membrane down a pressure gradient. Along this bulk transfer of plasma water, a great proportion
12

of middle-sized water-soluble molecules (500-5000 Dalton) are dragged across the membrane for
removal. Dialysate that has been used is pumped out of the dialysis machine for disposal and the
filtered blood is returned to the patient through the venous line.
Adequacy of HD treatment refers to the delivery of the treatment dose that is sufficient
enough to promote the patient’s well-being55. It is conventionally assessed by the clearance of
small solutes, mainly urea. Urea clearance is commonly represented in terms of urea reduction
ratio index, quantified using acquired levels of blood urea nitrogen before and after the treatment56
and through the quantification of Kt/V index where, K is the dialyzer blood water urea clearance
(L/hr), t is the dialysis time (hr), and V is the volume (L) of water in the body57. The Kt/V index is
the most widely used and a minimum single pool dose of 1.2 per dialysis is recommended.
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Figure 1-3 Hemodialysis circuit diagram. Recreated from Hemodialysis by NIH: National
Institute of Diabetes and Digestive and Kidney Disease, 2018.

1.2.4 Complications of HD
Common acute CV complications that occur with HD treatment are hypotension,
hypertension, and arrythmias58. A reduction in BP or hemodynamic instability during HD is a
direct response to the ultrafiltration and the rapid removal of fluid in attempts to achieve dry
weight59–67. There are a few approaches to managing hypotension during dialysis. For example,
intradialytic hypotension can be managed by reducing and maintaining a steady, constant
ultrafiltration rate as well as increasing the dialysate sodium concentration to prevent decline in
plasma osmolality and protect extracellular volume68–71. Recent studies have also demonstrated
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controlling the temperature of the dialysate to cool or isothermic (below 36.5°C) levels can
contribute to hemodynamic stability and improve patient tolerability to dialysis treatment72–76.
While ultrafiltration during HD reduces BP in most patients, up to 15% of HD patients
demonstrate paradoxical increases in BP during dialysis, and this is referred to as intradialytic
hypertension77–79. Furthermore, hypertension outside of dialysis is prevalent in 70-90% of patients
and is associated with adverse events. Management of intradialytic hypertension includes reduction
in dry weight, antihypertensive pharmacological therapy, increasing the frequency of dialysis
sessions, and reducing dialysate sodium concentration.
Ventricular and atrial arrhythmias are common causes of sudden cardiac death in the HD
population80–89. Studies have utilized implantable loop recorders for continuous monitoring of
irregular heart rhythms and have demonstrated high prevalence of bradycardias and atrial
fibrillations90,91. It was revealed that rates of clinically significant arrhythmias were highest at the
first dialysis session of the week in patients receiving HD thrice weekly and the frequency of
episodes increased during the last twelve hours of the interdialytic interval. These findings could be
due to the fluctuation in fluid and electrolyte levels during dialysis and other studies have suggested
dialysate potassium concentration to be a contributing factor. However, the mechanism of HD
induced arrhythmia remain unclear and further investigation is needed.

1.2.4.1
1.2.4.1.1

Effects of HD induced Circulatory Stress
Endothelial Dysfunction

The proper functioning of the microcirculation and its endothelial cell layer is important
for CV function.92 Endothelial dysfunction is known to occur in CKD patients undergoing HD,
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possibly contributing significantly to CV dysfunction such as defective BP control, impaired
vasodilation, ischemic tissue injury, and increased inflammation93–95.
The mechanisms by which endothelial dysfunction contributes to CV dysfunction include
impaired release of endothelial nitric oxide (NO) secondary to reduced endothelial NO synthase
activity93,94. NO is a vasodilator, an anti-inflammatory, and an inhibitor of platelet aggregation96,97.
Impaired vasodilation results in impaired circulatory autoregulation which has implications for
altered perfusion in vascular beds such as the heart and brain, especially in situations of circulatory
stress such as during dialysis. Loss of the anti-inflammatory and anti-platelet effects of NO due to
endothelial dysfunction may exacerbate the pro-inflammatory state of CKD patients and contribute
to atherosclerosis98–100 in this population.
It is thought that the dysregulation of the renin-angiotensin-aldosterone system in CKD
induces endothelial dysfunction primarily due to the dysregulation of angiotensin II101,102. This
assertion is supported by prior studies observing that increased levels of angiotensin II increased
the levels of reactive oxygen species and promotes vascular inflammation94,103. It has also been
shown that increased levels of reactive oxygen species results in oxidative excess and leads to
diminished NO. In fact, in patients with CKD, markers of oxidative excess correlates with markers
of endothelial dysfunction.
As discussed previously, one of the most common causes of CKD and ESRD is
nephropathy secondary to diabetes. In diabetes, insulin signaling is altered, downregulating the
expression of endothelial NO synthase activity, resulting in decreased NO release, with the CV
consequences as described above104,105. Advanced glycation end products are also produced in
states of hyperglycemia such as diabetes, which also impair endothelial function106–108. With
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reduced GFR in CKD, clearance of advanced glycation end products is impaired, creating a vicious
cycle of endothelial dysfunction.
Importantly, endothelial dysfunction may be induced by the life-saving HD treatment that
patients with renal disease rely on. Coupled with the fact that endothelial dysfunction may not only
be related to cardiovascular disease such as impaired myocardial perfusion and contractility, but
may in fact precede it, it is crucial that endothelial dysfunction be sensitively assessed in the CKD
and hemodialysis population. As discussed further in this thesis and as demonstrated in the work,
one method to measure endothelial dysfunction is via plasma syndecan-1 levels.
Endothelial dysfunction has been assessed by quantification of injury to the endothelial
surface layer. The endothelial glycocalyx is a protective barrier overlying the monolayer of
endothelial cells that line the blood vessels, and its degradation is an early indicator of endothelial
damage109,110. The glycocalyx is comprised of cell-bound proteoglycans (e.g., syndecan protein
family) which are bound to glycosaminoglycan side chains (e.g., heparan sulfate), and this layer
protects the endothelium from damage by direct interaction with ions and proteins that are present
in the plasma109. Degradation of the endothelial glycocalyx can result from sepsis, prolonged
hyperglycemia, and ischemic-reperfusion injury, which ultimately causes ‘shedding’ of its
constituents into the circulation. Syndecan-1 is a protein in the heparan sulfate proteoglycan, and
elevation of this glycocalyx constituent in serum correlate with damage to the glycocalyx111.
Clinical studies have shown glycocalyx damage in kidney disease that is associated with
endothelial dysfunction and the level of glycocalyx damage, marked by increased glycocalyx
constituent ‘shedding’, is proportional to kidney dysfunction (i.e., markers of glycocalyx shedding
increased incrementally with CKD stages)111,112. This marked damage to the glycocalyx is the
precursor to injury or dysfunction of the endothelium.
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Exactly how glycocalyx damage results in endothelial dysfunction is still an active area of
research. One possible mechanism is that the molecular structure of glycocalyx molecules such as
syndecan-1 results in their oscillation when exposed to fluid (blood) flow, generating a lifting force
that keeps red blood cells away from the endothelial cell and allows them to glide with minimal
friction along the vascular endothelium113,114. The electrostatic charge of the glycocalyx also helps
with this. Damage to the glycocalyx results in the loss of this lifting force, increasing friction to
blood flow, with implications for microvascular resistance and perfusion113,114. A second possible
mechanism is the mechanical coupling between the glycocalyx and the endothelial cell’s actin
cytoskeleton113,114. Shear forces on the glycocalyx creates tension on the actin cytoskeleton
triggering a signaling cascade resulting in production of NO. This mechanical relationship is
modulated by osmotic stress and hydrostatic stress as these stresses can result in remodeling of the
actin cytoskeleton113,114. This has implications for the endothelial cell’s ability to produce NO,
with the resulting cardiovascular consequences as discussed above.

1.2.4.1.2

Large Vessel Disease in Uremia

In non-CKD patients, atherosclerosis is characterized by plaque development in the intimal
layer of the arteries. Lipoproteins composed of proteins, phospholipids and lipids are deposited in
the underlying smooth muscle of the intima layer, initiating proliferation of fibrous tissues115. With
the formation of the atherosclerotic plaque (Figure 1-4), the conduit function of the artery is
disturbed by the restriction of blood flow and induces ischemia to tissues downstream of the
narrowed region, leading to myocardial damage. Risk factors of atherosclerosis in non-CKD
population include high cholesterol, hypertension, smoking, diabetes mellitus, obesity, and age.
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Figure 1-4 Progression of atherosclerosis. Recreated from Late complications of atherosclerosis
by Wikimedia Commons, 2020.

Coronary artery disease (CAD) is highly prevalent in ESRD and the underlying
pathogenesis of atherosclerosis in this cohort of patients is from the local inflammatory response
to endothelial dysfunction. In autopsy studies, coronary plaques in ESRD have been documented
in its advanced stages with heavy calcification in the medial layer, deposited as phosphate, with
an increased media thickness which differed from the mostly fibroatheromatous plaques of nonrenal patients116 (Figure 1-5). The degree of calcification was also shown to increase with longer
exposure to dialysis treatment117,118. Investigations to date questioned the mechanism of
accelerated atherosclerosis and it was hypothesized that the rate of plaque growth in CKD
increased with decrease in renal function, which possibly was responsible for the high CV event
rate in this group. However, the acceleration and nature of atherosclerotic plaque in ESRD remains

19

a topic of debate119–123. Diagnosis of CAD in CKD is discussed further in section 1.3.4.1 of this
chapter.
Normal Coronary Artery

CKD related CAD

-

No calcification

No atherosclerotic
plaque

Heavily calcified
atherosclerotic plaque

Calcified
atherosclerotic plaque

-

Contains normal endothelial cells
No calcification
Organized smooth muscle

Calcification

Calcification

Generally, no
calcification

No Plaque
Intima

Media

Non-CKD CAD

Figure 1-5 Morphology of coronary artery in chronic kidney disease. Recreated from Diagnosis
and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review
by Mathew et al., 2017.

Risk factors for atherosclerosis in CKD include mineral bone metabolism, vascular
calcification, uremic toxins, inflammation, oxidative stress, and endothelial dysfunction; all of
which are commonly experienced in patients undergoing HD120,124. In this thesis, we aim to further
evaluate the compounding effects of CAD and HD-induced circulatory stress on cardiac function.

1.2.4.1.3

Structural and Functional Cardiac Injury

Although dialysis is a life-saving treatment for patients with CKD, their CV comorbidities
make them susceptible to HD-induced cardiac injury. In this patient population, there is a high
prevalence of CAD125, as well as increased peripheral artery stiffness126. Increased peripheral
artery stiffness results in increased peripheral vascular resistance and ultimately left ventricular
hypertrophy (LVH) a common finding in CKD patients127. Microcirculatory changes in patients
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with CKD have also been reported. Together, larger vessel and microcirculatory changes result in
reduced coronary flow128–130, while LVH result in increased myocardial demand. The reduced
ability to increase coronary blood flow to match the increased myocardial demand creates a flowdemand mismatch, reducing the ischemic threshold and creating susceptibility to demand
ischemia.
Because of this, the circulatory stress imparted by dialysis treatment is enough to induce
acute reversible segmental myocardial hypoperfusion and contractile dysfunction131–133. Repeated
dialysis treatments cause recurrent ischemic injury, although initially reversible, eventually
accumulates into long-term loss of segmental and global cardiac contractility. The amount of
injury may be related to the amount of relative hypotension experienced by the patient during HD
as well as the rate of ultrafiltration during dialysis. Defective BP control due to impaired baroreflex
sensitivity, decreased vascular compliance, and microvascular/endothelial dysfunction in CKD
patients may also contribute to the amount of injury126.
However, the relative contributions of the macro-cardiac circulation (i.e., CAD) versus the
micro-cardiac circulation (i.e., endothelial dysfunction) remains unclear. This exact question is
investigated in this thesis.
If relative hypotension is one of the main factors determining the amount of HD-induced
cardiac injury, it then follows that therapies targeted at improving the hemodynamic response
during dialysis may be protective against HD-induced cardiac injury. As discussed previously,
therapies

that

have

been

studied

include

dialysate

cooling73–76,

remote

ischemic

preconditioning134,135, and intradialytic exercise136–152. Intradialytic exercise as a cardioprotective
therapy is further investigated in this thesis.
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1.3 Imaging Modalities to Assess HD-induced Myocardial and
Microcirculatory Injury
The acute changes to a patient’s heart function during HD treatment are still not fully
elucidated. Imaging offers a non-invasive means to explore these changes and to shed light on how
to effectively address the associated clinical concerns. Currently available imaging modalities can
identify morphological and functional changes to the heart during dialysis and may be sensitive
enough to detect the heart’s response to cardioprotective interventions. Here, we describe and
compare currently available and emerging modalities for intradialytic myocardial assessment and
discuss the latest insights gleaned from recent imaging studies exploring HD-induced myocardial
dysfunction. In particular, we focus upon new developments in cardiac CT which can allow the
totality of cardiac structure and function to be imaged, at rest and under the stress of HD.

1.3.1 Positron Emission Tomography
A number of research studies have investigated the functional changes within the
myocardium associated with dialysis treatment using position emission tomography (PET).
Radioactive tracers such as 13N-Ammonia or 15O-labeled water are administered intravenously to
quantitatively measure myocardial perfusion133,153. A metric called myocardial perfusion reserve
(MPR) can then be calculated from perfusion measurements at rest and during a stress test, and is
defined as the global myocardial perfusion at stress normalized to the myocardial perfusion at
rest154,155. MPR reflects the capacity at which the vascular bed responds to a maximal increase in
perfusion and is considered a surrogate measure of endothelial dysfunction. To ensure a maximal
increase in perfusion during stress, a pharmaceutical agent is typically administered to induce
systemic vasodilation. Adenosine, dobutamine, and dipyridamole are commonly used vasodilators
during this test.
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Research teams have conducted intradialytic PET studies investigating the change in
myocardial perfusion during a single dialysis session. A case study reported a significant decrease
in myocardial perfusion at peak dialysis stress (220 minutes of HD) relative to both baseline and
early dialysis (30 minutes of HD). Similarly, McIntyre et al. reported an acute decrease in global
myocardial perfusion during HD133. They also showed that PET measurements can be
complementary to ultrasound measurements, as myocardial segments developing RWMAs had
significantly greater reductions in perfusion.
Despite its use in current clinical practice, a major limitation of PET imaging is its
accessibility. PET tracers with the best performance have short half-lives and require additional
on-site access to cyclotron facilities to produce the isotopes for immediate utilization. Another
drawback of PET imaging is its poor spatial and temporal resolution which limits the
morphological or anatomical information it provides. Due to the low spatial resolution of PET, CT
images may also be acquired concomitantly for anatomical reference using a PET/CT hybrid
scanner. This provides additional structural information but no additional information about
contractile function.

1.3.2 Magnetic Resonance Imaging
1.3.2.1

Four Dimensional MRI to Assess Contractile Function

Magnetic resonance imaging (MRI) is a powerful and versatile modality capable of
obtaining detailed local and global mechanical function of the myocardium. Zerhouni et al. was
first to describe the use of tissue tagging to track the motion of the myocardium in fourdimensions156. Tissue tagging is achieved by using magnetization saturation to null the signal from
specific spatial locations in the tissue. These signal voids can then be used as dark fiducial markers
to track movement, allowing the calculation of mechanical parameters that describe the regional
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wall motion of the myocardium in HD population157. These parameters include strain, strain rate,
twist and torsion.
Strain is defined as the ratio of the change in length of the myocardial fibers to their initial
dimension and can be measured in 3D158,159. Measurement of radial, circumferential, and
longitudinal strain enables the calculation of the 3D deformation of myocardial wall. The rate at
which strain changes over time can also be determined. Both 3D deformation and strain rate are
considered measures of left ventricular (LV) function and are sensitive indicators of ventricular
wall remodelling. On the other hand, twist and torsion are parameters that indicate the amount of
opposing rotation between the base and apex of the heart and are considered to be sensitive to
changes that occur in both systolic and diastolic dysfunction.
There are many inherent limitations of 4D MRI. As tissue tagging involves a continuous
sequence of (radiofrequency) pulses to create the signal voids, increased energy deposition in the
tissue and non-uniform tag intensity can occur158. Also, because the tags are created using
magnetization saturation, they will fade with time due to T1 relaxation. This can lead to
inaccuracies in the measurement of myocardial wall motion especially in diastole.

1.3.2.2 Exogenous and Endogenous Contrast MRI for Assessment of
Perfusion
In exogenous contrast-enhanced MRI, a gadolinium-based contrast agent is administered
to the patient prior to the scan. A dynamic image is acquired, and a tracer kinetic model is applied
to the measured local blood volume to estimate perfusion160. This validated technique offers high
spatial and temporal resolution images of the heart. However, in patients with impaired kidney
function, there is a risk that injecting gadolinium could precipitate nephrogenic systemic
fibrosis161. Newer formulations of gadolinium contrast have reduced these risks but use in patients
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receiving maintenance dialysis is still discouraged. Therefore, in a cohort of CKD population,
taking advantage of an endogenous tracer of blood flow is a favorable option.
Arterial spin labelling (ASL) is a non-invasive imaging technique that magnetically labels
the protons of water in the blood and uses it as a free diffusible endogenous tracer155,160. Protons
are labelled by an inversion pulse, which inverts its magnetic spin. After a delay to allow the
labelled blood to flow into and perfuse the tissue of interest, the tissue is imaged. As perfusion
occurs, the labelled protons in the blood exchange with protons in the tissue, resulting in a
reduction of signal. A perfusion weighted image can then be generated by taking the difference
between a labelled and a non-labelled image.
A short-term trial studying the effects of hemodiafiltration, and HD on CV response
utilized intradialytic ASL-MRI to detect a decrease in myocardial perfusion during dialysis
treatment to baseline157. These results are broadly comparable to studies done using PET,
suggesting that MRI, a more accessible technique, may be able to provide similar information to
PET.

1.3.2.3

MRI to Assess Tissue Viability

There are many specialized MRI sequences that can be used for assessing specific changes
to the myocardium. For example, T1-weighted images can be used to detect fat, fibrosis, and
calcification, while T2-weighted images can identify areas of infarct, edema, and inflammation162–
164

. Both types of images can be used concurrently to study the progression of a chronic CV disease

over time, as well as the identification of viable myocardium post ischemic injury165–168.
Cardiac MR imaging remains challenging because of the long acquisition time, which
needs to be minimized to reduce the effects of inherent cardiac and breathing motion. In almost all
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cases, steady breathing or breath-hold techniques are necessary for producing high quality images.
Improper breath-holds result in motion artefact and inaccurate measurement of perfusion.
Although patients with CV disease could benefit from MR imaging, many struggle to comply with
breathing directions and coaching; especially when multiple repeated acquisition is necessary for
signal averaging to improve the signal-to-noise ratio (e.g. ASL). In HD research studies,
combining high field magnets with HD equipment is very challenging and further limits the
application of these techniques to HD-based CV challenges.

1.3.3 Echocardiography
Echocardiography is an imaging tool that uses high frequency ultrasound waves to produce
two-dimensional images of the heart in real-time. Ultrasound is a popular imaging modality
because it is readily accessible in the clinic and can be used at the bedside. Operators can quickly
image the heart from different directions by positioning the ultrasound probe accordingly. Each
cardiac view is useful in examining the overall morphology of the heart, its ability to pump blood,
and the condition of the heart valves. In addition, stenosis, hyper- or hypotrophy, and tumor growth
can be detected with ultrasound.
Cardiac ultrasound images can also be processed to determine global and segmental
longitudinal strain of the myocardium and assess regional wall motion abnormalities (RWMA),
providing a direct measurement of the contractile performance of the heart. The development of
RWMAs reflects myocardial segments that reduce in contractile function during dialysis as a
consequence of regional ischemia. Assa et al. analysed echocardiography data from 105 patients
and detected HD-induced RWMAs in 29 of them169. In a similar proportion of patients, Dubin et
al. reported worsening RWMAs due to HD and found that patients with a previous diagnosis of
heart failure had a higher risk of worsening RWMA during HD131. Since dialysis patients who
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develop RWMAs during HD have a higher 1-year mortality, intradialytic echocardiography may
be able to identify patients who are more vulnerable to complications associated with dialysis.
Measuring RWMAs with echocardiography could also be a useful metric for assessing
physiologic response to interventions. An exploratory study by Penny et al., which investigated
the effect of exercise for immediate cardio-protection against ischemia, demonstrated that
intradialytic exercise is an effective preconditioning approach that significantly reduced the
incidence of acute HD-induced cardiac injury, as quantified by a decrease in RWMAs148.
LV ejection fraction and LV systolic function can also be quantified using
echocardiography, providing a measurement of heart function. In addition, recent advancements
in echocardiography have proven capable of acquiring myocardial perfusion information in real
time with continuous intravenous administration of a contrast agent (e.g., microbubbles)170.
Dynamic perfusion measurements provide invaluable information about the microvasculature
abnormalities of the myocardium. However, perfusion imaging with myocardial contrast
echocardiography has yet to be adopted in HD studies for several reasons. First, a very low
mechanical index (related to the energy delivered by ultrasound) must be maintained to visualize
the injected contrast. Second, echocardiography comes with an inherent limitation in image
resolution. Third, image artefacts are common when imaging the heart as a result of its dynamic
contractile movement, its positioning adjacent to the lungs, and its motion during respiration.
Many other imaging modalities have overcome these limitations and will be discussed later on.
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1.3.4 Principles of Computed Tomography Imaging
1.3.4.1

Coronary CT Angiography

Coronary angiography (CA) is not a tool for imaging acute dysfunction during HD. Rather,
it is used to assess the chronic effects of renal impairment and dialysis on the coronary arteries to
provide an assessment of flow limiting stenosis in the coronary circulation. Although traditionally
performed with invasive cardiac catheterization, CA can be performed with different non-invasive
imaging modalities, many of which enable three-dimensional acquisition of coronary angiograms
in high resolution. Not only can CA assess the degree of luminal narrowing, but it can also detect
areas of calcification within the wall of the coronary arteries themselves – first quantified by
Agatston171.
The use of CA in HD patients is considered clinically relevant as excess coronary artery
calcification (CAC) is common in this patient population and is associated with high CV risk172–
177

. It is a common misconception that the origins of CV mortality in all stages of CKD are

equivalent. In non-uremic CKD patients, arterial calcification is predominantly due to
atheromatous plaques derived from the vessel intima130,178. For these patients, plaque burden is
characteristically high and progresses rapidly. In patients with worsening degrees of CKD (and in
particular those requiring dialysis, i.e. uremic CKD patients) the origin of the calcifications is
different from that of non-uremic patients. Calcifications in uremic CKD patients commonly
express bone-associated protein as well as the core-binding factor a-1, and arise from the arterial
media rather than the intima176,178. CAC scoring used to assess the amount of calcium deposits in
the arteries provides a measurement of intimal calcification (as a measure of plaque burden) and
medial calcification (effecting arterial compliance). The CAC score is an essential measure for CV
risk stratification as both of these entities contribute to increased CV risk.
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Conventional cardiac CT angiography provides accurate assessment of coronary arterial
calcifications (as compared to other imaging modalities such as intravascular ultrasound,
fluoroscopy, and MRI)179,180. Contrast-enhanced CT angiography not only quantifies vascular
calcifications, but also detects coronary artery stenoses which can put a patient at risk for HDinduced myocardial ischemia. However, conventional CT angiography provides no functional
information on myocardial viability. To overcome this limitation, current studies have adopted
new cardiac CT protocols that allow simultaneous acquisition of perfusion and angiography in a
single dynamic heart scan. These protocols increase the amount of information we can obtain from
the patient, while keeping radiation exposure low.

1.3.4.2

Overview of Myocardial CT Perfusion Imaging

In the recent decade, CT scanners have become widely used with the introduction of high
slice system from 64 to 256, to even 320-slice scanners. The newer generation of scanners utilize
faster gantry speed rotation, improved image reconstructive software, and a more sensitive detector
to permit ultra-low dose cardiac imaging181,182. A faster gantry rotation speed can reduce cardiac
and breathing motion artefact during a scan, while improved iterative and model based
reconstructive software can significantly reduce the number of x-ray projections required for
diagnostic quality thereby lessening the radiation dose. In addition to technological advancement
of the scanner itself, new acquisition techniques have also been introduced with the goal of
achieving clinical utilization of cardiac CT. So far, these techniques have yet to make their way
into clinical practice but are available for research purposes.
As discussed previously, current clinically available imaging modalities are each
individually useful in acquiring specific information about particular aspects of myocardial
dysfunction. For patient assessment and CV research, multiple imaging modalities are usually used
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in combination to obtain a more complete understanding of the pathophysiology at hand. This
requires additional resources and time that often make the use of multi-modality imaging infeasible
in the clinic and impractical in a research setting. In particular, using multiple imaging modalities
during an HD session to assess intradialytic changes in myocardial function is very difficult to
accomplish. However, an advanced CT system in parallel with novel imaging techniques that can
acquire high quality information about multiple aspects of myocardial dysfunction in one rapid
scanning session would be ideal for assessing the structural and functional changes of the heart in
response to HD.
Dynamic contrast-enhanced (DCE)- CT is an x-ray imaging modality that quantifies the
enhancement of tissue over time as a bolus of injected iodine contrast washes in and out of the
tissue. A common concern with dynamic imaging is an increase in radiation exposure resulting
from the frequent number of scans per imaging session. To overcome this, recent advancements
in CT scanners have made prospective ECG-gating possible, allowing for the reduction of effective
radiation dose to the patient from 12mSv to 3mSv. This is because images are acquired during a
specific phase (often diastolic) of the cardiac cycle rather than over the whole cardiac cycle. A
further benefit is that this approach also reduces the cardiac motion between each image slice. This
is especially important because motion artefacts hinder the accuracy of perfusion measurements.
To further reduce radiation exposure, there are approaches including decreasing the tube voltage
or acquiring half the number of x-ray projections, but discussion of these techniques is beyond the
scope of this article.
Following a dynamic scan, a tracer kinetic model that mathematically describes the
delivery of contrast from the intravascular to the extravascular components of the tissue is applied
to the DCE-CT image to generate functional maps of physiologic parameters such as myocardial
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perfusion, blood volume, mean transit time, and extravascular contrast distribution volume
(ECDV). Thus, a single dynamic scan can simultaneously provide valuable functional information
about multiple aspects of myocardial dysfunction.

1.3.4.3

Dynamic CT Imaging for Myocardial Perfusion

Cardiac DCE-CT is a comprehensive imaging technique that can extract information on
myocardial dysfunction, ischemia, tissue viability, fibrosis, edema, and coronary calcification
from a single scan. It can also track changes in cardiac morphology during the progression of
dialysis treatment. In the case of myocardial dysfunction during HD, it is well established that
most treatment sessions introduce recurrent ischemic injury and stunning of myocardial segments.
Following repeated treatment and recurring ischemic episodes, affected tissue will no longer be
viable. With DCE-CT imaging, this can easily be identified as hypoperfused regions of interest in
a myocardial perfusion map (Figure 1-6) that correspond to decreased blood volume. As the
repetitively stunned myocardial tissue becomes irreversibly damaged over time, cell membranes
within the region degenerate and become ‘more permeable’, allowing extravasation of iodine
contrast to the intracellular space. To quantitatively distinguish viable from infarcted tissue,
consideration of the intracellular compartment is necessary. To do this, So et al. developed the
extended Johnson-Wilson-Lee tracer kinetic model and defined a new functional parameter,
ECDV183,184. Quantitative measure of ECDV can also be used to detect myocardial fibrosis in HD
as the same tracer kinetic model can be used to demonstrate an increased contrast distribution to
the fibrotic tissue relative to normal tissue.
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Figure 1-6 Morphological change in LV myocardium during an intradialytic CT imaging session.
Perfusion images of HD patient at three time points: A) Before dialysis B) Peak dialysis; 225
minutes into HD C) Post dialysis. A decrease in global myocardial perfusion (ml/min/100g) is also
demonstrated throughout the dialysis session. Adapted from Current and novel imaging techniques
to evaluate myocardial dysfunction during hemodialysis by Hur and McIntyre, 2020.
Perfusion heterogeneity has been reported as a marker of endothelial dysfunction in the
dialysis population. In 2018, Kharche and colleagues quantified myocardial perfusion
heterogeneity in peritoneal dialysis patients using DCE-CT via fractal dimensions to test whether
or not dialysis increased heterogeneity185. The same approaches can be applied to HD.
Qualitatively, a case study demonstrated a significant increase in perfusion heterogeneity at peakand post-HD relative to baseline (Figure 1-7). A patient with a prior history of peritoneal dialysis
demonstrated an increase in perfusion heterogeneity during HD (Figure 1-8), consistent with
previous studies that concluded HD stresses the myocardium more than PD.
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Figure 1-7 Myocardial CT perfusion (ml/min/100g) image of a HD patient at pre-dialysis (A),
peak-dialysis (B), and post-dialysis (C). White arrows denoting increased perfusion heterogeneity
throughout the left ventricular myocardium as the patient progresses through dialysis treatment.
Adapted from Current and novel imaging techniques to evaluate myocardial dysfunction during
hemodialysis by Hur and McIntyre, 2020.

Figure 1-8 Myocardial CT perfusion (ml/min/100g) image of a single patient. Panel A during
peritoneal dialysis and panel B during HD. It is qualitatively evident by the uneven, speckle-like
perfusion effect seen in panel B that there is greater perfusion heterogeneity during HD treatment
compared to peritoneal dialysis in the same subject. Adapted from Current and novel imaging
techniques to evaluate myocardial dysfunction during hemodialysis by Hur and McIntyre, 2020.
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There is a lot of potential for DCE-CT in terms of studying the hemodynamic effects of
HD treatment and assessing HD patient responses. Not only can it measure multiple markers of
myocardial dysfunction with high spatial resolution, it can do so in a rapid, single dynamic scan
that allows patients to free-breathe. With the availability of these various radiation-reducing
measures, the clinical benefit from the high-quality data provided by DCE-CT would outweigh the
risks of radiation. The accessibility of CT and the short acquisition times offer additional
advantages that enable increased clinical throughput. Multiple CT approaches (e.g. CT perfusion
and CT angiography) can also be performed simultaneously to acquire even more complete
morphological and functional information, as discussed previously. However, it is important to
note one limitation to this technique. When generating functional maps such as perfusion, blood
volume, and mean transit time maps, a tracer kinetic model must be used. This tracer kinetic model
is selected based on the pathophysiology specific to a disease. In other words, different models are
used for different pathophysiology, and selecting the correct model is essential for accurate
quantification of functional data.

1.3.4.4

Risks Associated with CT Contrast Agents

Contrast-induced nephropathy has historically been an important concern for those with
renal impairment. Most clinical research involving CT has therefore excluded participants with
low residual renal function. However, recent studies investigating the effect of contrast agents on
residual renal function found no evidence of contrast-induced nephropathy186. The benefits of
contrast-enhanced imaging in patients with high CV mortality rate therefore outweigh the potential
harm.

34

1.4 Motivation and Objectives of Thesis
The overarching goal of this thesis work is to study the acute effect of HD on the circulation
at multiple levels—macrovascular, microvascular, and at the endothelial level—under conditions
of intradialytic exercise and varying levels of dialysate sodium concentration. To address this
overarching hypothesis, this thesis has been divided into three research projects (Chapters 2, 3,
and 4) and the individual objectives are as follows:
Project 1: The effect of coronary artery disease on myocardial perfusion and stunning response
to HD treatment
o Examine how coronary artery disease affects global myocardial perfusion during HD
o Examine how coronary artery disease affects segmental myocardial perfusion during HD
o Examine the effects of coronary artery disease on myocardial stunning during HD
Project 2: Investigating the role of dialysate sodium concentration on the endothelium and
microcirculation during HD
o Examine endothelial injury and microvascular perfusion defect as a result of HD treatment
o Study the effect of dialysate sodium on endothelial injury and microvascular perfusion
o Explore the relationship between endothelial injury and microvascular perfusion with
respect to dialysate sodium concentration
Project 3: Assessment of intradialytic exercise for cardioprotection to HD-induced circulatory
stress
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o Investigate the acute effect of intradialytic exercise on the endothelium during HD
o Examine how intradialytic exercise affects global myocardial perfusion during HD
o Assess whether or not intradialytic exercise improves ischemic tolerability of HD treatment
through measures of myocardial stunning
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Chapter 2

2 Presence of coronary artery stenoses reduces segmental
myocardial perfusion and is associated with myocardial
stunning
A version of this chapter is in preparation for publication: Lisa Hur, Ali Islam, Jarrin Penny, Justin
Dorie, Christopher W. McIntyre, “Presence of coronary artery stenoses reduces segmental
myocardial perfusion and is associated with myocardial stunning,” In preparation. Aug 2022.

Abstract Hemodialysis (HD) is associated with repetitive ischemia-reperfusion cardiac injury
occurring during each treatment that accumulates with subsequent treatments. Conventional
cardiovascular therapies effective in patients with atherosclerotic disease or myocardial infarction
have been largely ineffective in treating HD-induced injuries. The objective of the present study
was to use coronary CT angiography (CCTA), intradialytic CT perfusion and echocardiography
imaging to noninvasively evaluate the myocardial perfusion and stunning response during HD in
patients with and without coronary artery disease. CCTA images were acquired prior to HD
(baseline) on thirteen patients and assessed by an experienced radiologist for clinically significant
stenoses. In addition, dynamic contrast-enhanced CT scans (Revolution CT, GE) were conducted
at baseline, peak HD stress, and 30 mins post HD. The dynamic CT images were analyzed using
the Johnson-Wilson-Lee tracer kinetic model to quantify global myocardial perfusion (MP) of the
left ventricular myocardium. Following each dynamic CT scan, apical 4-chamber and 2-chamber
views of the heart were acquired with 2D echocardiography (Vivid Q, GE). The systolic function
was evaluated by measuring segmental longitudinal strain (LS) using commercially available
software (EchoPAC, GE). Myocardial segments demonstrating >20% reduction in LS compared
to baseline were defined as regional wall motion abnormalities (RWMA). Three patients were
identified with asymptomatic coronary artery disease (CAD+). In participants with stenoses, there
were no significant intradialytic changes in global MP. HD participants with no identifiable
stenoses lesions (CAD-) demonstrated a decrease in global MP from baseline to peak HD and a
recovery of perfusion to baseline level at post HD timepoint. Furthermore, CAD+ participants had
elevated number of myocardial segments experiencing RWMA that remained elevated post HD.
The presence of coronary artery disease alters myocardial perfusion and stunning response to HD
treatment.
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2.1 Introduction
Cardiovascular disease (CVD) is highly prevalent in end stage renal disease (ESRD) and
is the major cause of morbidity and mortality1–6. Vascular dysfunction induced by uremia in ESRD
is a potential underlying cause of these complication7,8. The interplay of uremic toxins such as
guanidine compounds, advanced glycation end products, p-cresyl sulfate, indoxyl sulfate and
asymmetric dimethylarginine promote the progression of atherosclerosis9. In an autopsy study, the
intima-medial layer of the artery thickens with decreased renal function leading to arterial stiffness,
a loss of vascular wall compliance10. The alteration in hemodynamics caused by arterial stiffening
induces left ventricular hypertrophy associated with coronary hypoperfusion. Naturally, it can be
assumed that a coronary perfusion compromise would alter myocardial perfusion producing
ischemic regions in hypoperfused areas of the heart.
As part of the progression of atherosclerosis and arterial stiffening in uremic patients on
hemodialysis (HD), vascular calcification of the intimal and medial layer is commonly seen1. The
vascular calcification can be deleterious and have been shown to be associated with arterial
stiffening and endothelial dysfunction11,12. This current study questions the effect of vascular
dysfunction of the coronary arteries on the microvascular perfusion and cardiac function during
HD.
During the HD treatment, multiple vascular beds experience ischemia and reduction in
oxygen delivery, followed by reperfusion at the end of the dialysis treatment. A single episode of
HD treatment exerts significant hemodynamic instability that can potentially lead to intradialytic
hypotension, defined as greater than 20 to 30 mmHg decrease in systolic blood pressure13–18. This
degree of circulatory stress and hypotension is associated with myocardial stunning and is due to
the considerable reduction in intravascular volume as a result of the removal of large amounts of
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fluid that is not adequately negated by plasma refill during dialysis19. Studies investigating the
frequency of intradialytic hypotension and its association to clinical outcome have identified this
significant reduction in systolic blood pressure in five to thirty percent of HD treatments,
dependent on the set threshold20–22. Furthermore, the frequency of intradialytic hypotension was
associated with increased patient mortality and hospitalization16,23–25. It is now common
knowledge that the administration of HD results in recurrent circulatory stress.
In conjunction with the hemodynamic instability experienced with HD, the high prevalence
of CVD and other comorbidities can further exacerbate the dialysis-induced ischemic injury26–38.
ESRD patients with diabetes mellitus have reduced coronary flow reserve in the absence of
angiographically evident coronary artery disease (CAD)39. Similarly, utilizing transthoracic
doppler echocardiography, a study showed that HD patients without left anterior descending
stenoses had significantly lower coronary flow reserve than compared to those with normal renal
function40. These findings may be due to structural and functional cardiovascular abnormalities,
such as left ventricular hypertrophy and increase in left ventricular mass resulting from
hypertension that is commonly present in this cohort of patients41–44. Clinical studies using
advanced imaging techniques to assess coronary flow have also demonstrated a reduction in
myocardial perfusion in response to HD treatment, indicating that CAD is not a prerequisite for
myocardial ischemia experienced with HD37,45–47. It is clear that HD patients have a higher risk for
cardiovascular disease relative to the general population, which may be compounded by the
presence of existing CAD and vascular dysfunction. Since HD induces challenges to tissue
oxygenation due to perfusion anomalies and consequently induce myocardial stunning, it would
be important to determine the effect CAD on perfusion during HD and evaluate whether or not
asymptomatic CAD in HD patient should be intervened.
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Therefore, the aim of this exploratory study was to identify flow restricting coronary artery
lesions in HD participants with asymptomatic CAD and observe HD’s effect on myocardial
perfusion and stunning using serial multimodal imaging during HD. Coronary artery status was
evaluated with coronary computed tomography (CT) angiography, myocardial perfusion was
quantified with dynamic CT perfusion imaging, and myocardial stunning was assessed with
echocardiography. It is hypothesized that HD is associated with an acute reduction in myocardial
perfusion that is independent of coronary artery status. However, the coupling of flow limiting
coronary artery lesions and HD-induced ischemia may affect the overall myocardial function,
marked by the severity of myocardial stunning.

2.2 Methods
2.2.1 Study Design
This study aims to investigate the effect of coronary artery status on the myocardial
response to HD. It is a single-centered cross-sectional study conducted on a cohort of ESRD
patients requiring maintenance HD. Participants who agreed to participate in the study were asked
to attend an intradialytic imaging session at St. Joseph Health Centre (London, Ontario, Canada).
During the study, a series of dynamic contrast enhanced CT images, echocardiography, and blood
samples were collected throughout the course of the dialysis treatment: prior to HD initiation
(baseline), at maximal HD-induced circulatory stress (peak HD) and following the recovery phase
after the return of blood (post HD). Collection of both blood and multimodal imaging enable the
evaluation of myocardial perfusion and the presence of myocardial stunning in relation to
intradialytic electrolyte changes.
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2.2.2 Study Population
Fourteen participants, eighteen years of age or older, were recruited from the London
Health Science Centre Renal Program (London, Ontario, Canada). Those recruited were required
to have received HD for a minimum of three months prior to study enrollment and undergo HD at
least thrice weekly. Prior to the initiation of the study, all participants enrolled provided informed
consent. The HD participants enrolled in this study were at random and none were suspected of
CAD. However, previous studies have suggested considerable plaque burden in this patient
population that may be subclinical. The exclusion criterion for the involvement of this study
included a history of chronic arrhythmia, being on anti-arrhythmic medications, and having
implanted cardiac devices such as a pacemaker or cardioverter defibrillator. A single participant
was removed from analysis as the coronary angiography image could not be acquired at the time
of the study visit.

2.2.3 Demographic Information
At the time of enrollment, the following demographic information was collected from the
participants: date of birth (month and year), biological sex, weight, height, ethnicity, and chronic
kidney disease related patient information. From the provided information, additional
demographics such as age and body mass index were calculated. Patient demographics are
summarized in Table 2-1.
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Table 2-1 Participant information and demographics
Characteristics
Ethnicity: Caucasian, n
Men, n
Age, yr
BMI
Dialysis vintage (mo)
Hemodialysis vintage (mo)
Charlson comorbidity index*
Congestive heart failure
Primary renal diagnosis
Hypertension
Hypertensive nephrosclerosis
Diabetic nephropathy
Acute Interstitial Nephritis
IgA nephropathy
Current Smoker
Medications
ACEi/ARB
b - blocker
2+ antihypertensive agent

Prevalence
10 (76%)
8 (62%)
66 ± 13
33 (26-41)
58 (20-141)
50 (16-141)
7.4 (4-12)
4 (31%)
4 (31%)
2 (15%)
6 (46%)
1 (8%)
2 (15%)
1 (8%)
5 (38%)
7 (54%)
4 (31%)

2.2.4 Dialysis Treatment Information
The study visits were conducted midweek and dialysis treatments were delivered on the
Fresenius 5008 dialysis machine using high-flux polysulfone dialyzers by a single operator (JP).
HD treatment duration ranged from three to four hours. The dialysate composition was prescribed
and delivered in accordance with the patient’s individual prescription as summarized in Table 22: sodium range 135 to 140 mmol/L, potassium range 1.5 to 3.0 mmol/L, calcium range 1.25 to
1.5 mmol/L, and bicarbonate range 35 to 40 mmol/L. Dialysate flow ranged from 500 to 800
mL/min, with six patients using an arteriovenous fistula, a single patient dialyzing with an
arteriovenous graft, and six dialyzing with a central line. Anticoagulation was achieved using low
molecular weight heparin and the dialysate temperature was 36.5°C for all patients.
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Table 2-2 Mean dialysis prescription (n=13)
Dialysis Prescription

Mean ± SD

Treatment Time (hr)
Sodium (mmol/L)
Calcium (mmol/L)
Bicarbonate (mmol/L)
Dialysis flow, Qd (ml/min)
Vascular Access (AVF: AVG: CVC)*

3.5 ± 0.7
139 ± 1.8
1.3 ± 0.1
37.6 ± 2.3
546 ± 113
6:1:6

*AVF = arteriovenous fistula; AVG = arteriovenous graft; CVC = central venous catheter

2.2.5 Assessment of Hemodynamic Stability
Intradialytic changes in systolic blood pressure were used as a marker of hemodynamic
stability. Measurements were acquired upon participants arrival and then periodically throughout
the dialysis session until thirty minutes following the end of HD treatment. Blood pressure
measurements were made with patients seated upright on the dialysis chair.

2.2.6 Assessment of Coronary Artery Status
Coronary CT angiography was routinely collected at baseline before commencing dialysis
for non-invasive anatomical assessment of coronary artery stenosis. To achieve the highest quality
image of the coronary arteries, a smart prep feature allowing real time monitoring of the contrast
agent as it enhances the descending aorta at low x-ray dose, was utilized to determine specific
parameters that are personalized to the patient being scanned. Once the parameters were set, the
prospectively ECG-gated scan was acquired at peak aortic enhancement of contrast during patient
breath hold. The scanning parameters are as follows: display field of view = 25.0 cm; 75%-75%
R-R interval; tube voltage = 100 kV; tube current = smart mA 600 – 700; detector coverage =
160mm; slice thickness = 0.625mm; gantry period = 0.28s. For contrast enhancement, iodine
contrast (Isovue 370, 0.7 mL per kilogram of body weigh)t was administered intravenously at an
infusion rate of 3 – 4 mL per second followed by a set 30 mL saline flush bolus at the same
injection rate.

59

The images were retrospectively reconstructed on the scanner console using an adaptive statistical
iterative reconstruction (ASiR) algorithm to further improve image quality and diagnostic value
(Revolution, GE Healthcare). The slice thickness was maintained during the reconstruction and
the processed images were transferred to a proprietary workstation for analysis (Advantage
Workstation, GE Healthcare). An experienced radiologist (A.I) reviewed the coronary anatomy
for clinically significant stenosis in the three major arteries: (1) right coronary artery (RCA), (2)
left anterior descending (LAD) artery, (3) left circumflex (LCx) artery. As per literature, coronary
arteries with greater than fifty percent narrowing of the vessel’s diameter were identified to be
stenosed lesions with potential hemodynamic significance. For each participant, the number of
coronary arteries and the specific arteries with the stenosis were recorded. Based on the reported
coronary artery status, the participants were divided into two arms. Individuals with one or more
coronary artery stenoses were distinguished into the ‘CAD+’ group while the remaining
participants with no reports of stenosed lesions were distinguished into the ‘CAD-’ group.

2.2.7 Dynamic Contrast Enhanced Computed Tomography
Prospectively ECG-gated, dynamic CT images of the heart were acquired at baseline, peak
HD stress), and post HD treatment. To quantify perfusion, iodinated contrast agent (Isovue 370)
was delivered during a series of axial scans that repeated every 1 to 2 heart beats (at approximately
1.5 seconds) was acquired. Participants were aligned on the CT bed in feet first-supine position.
The scanner settings for all dynamic CT images acquired for this study were as follows: display
field of view = 45.0 cm; 75%-75% R-R interval; tube voltage = 100 to 120 kV; tube current =
100mA; detector coverage = 160mm; slice thickness = 2.5mm; gantry period = 0.28s.
Retrospectively, the dynamic images collected at the three timepoints of HD treatment were
reconstructed at 5mm slice thickness using the ASiR algorithm to increase the signal to noise ratio
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(Revolution, GE Healthcare). Using a three-dimensional non-rigid registration algorithm,
correction for residual cardiac and respiratory motion was then applied to the images on a
proprietary workstation (GE proprietary software, advantage workstation, GE Healthcare).
Subsequently, the Johnson-Wilson-Lee model of tracer kinetics that characterizes the
delivery of the contrast agent was applied to the motion corrected dynamic image to generate
functional maps of the heart including absolute myocardial perfusion and blood volume. Maps
were generated for each slice of the dynamic image set. For the purposes of this study, only the
myocardial perfusion maps were examined.

2.2.8 Quantification of Global Myocardial Perfusion
The myocardial perfusion maps that were generated show the heart in the horizontal long
axis view as defined by the American Heart Association’s standardized myocardial nomenclature.
Seven slices of the left ventricular myocardium taken parallel to the horizontal long axis view were
selected (the mid slice, three slices posterior and three slices anterior to the selected mid slice) to
measure global myocardial perfusion. This was completed for maps generated from the dynamic
images acquired at baseline, peak HD stress, and following the end of HD.

2.2.9 Quantification of Segmental Myocardial Perfusion
The original perfusion images generated in the horizontal long axis view were rendered
into a three-dimensional volume and reconstructed to produce a standard short axis view of the
heart. Using the short axis view, the perfusion maps were segmented into sixteen myocardial
segments as defined by criteria established by the American Heart Association. Myocardial
perfusion was then quantified for each segment. Since the segments are anatomically defined, the

61

amount of myocardial perfusion corresponding to a particular coronary artery responsible for the
supply of blood to the particular segments could be quantified.

2.2.10

Assessment of Regional Wall Motion Abnormality

Standard apical 4-chamber and 2-chamber views of the heart was imaged with
echocardiography at baseline, peak HD stress, and post HD to study the effect of HD on myocardial
stunning. Each cardiac view was imaged over three cardiac cycles identified using a built-in, three
electrode ECG. A single cardiac cycle with the highest level of image quality was selected for
calculation of longitudinal strain. Using an offline two-dimensional speckle tracking proprietary
software (EchoPac, GE Healthcare), segmental longitudinal strain values were calculated for
twelve myocardial segments visualized in the 4-chamber and 2-chamber views. This was
completed for all intradialytic timepoints (baseline, peak HD stress, post HD treatment).
Calculating segmental longitudinal strain allowed the identification of segments exhibiting
regional wall motion abnormalities (RWMAs). RWMAs are defined by a decrease in longitudinal
strain during HD relative to the baseline strain values, representing a loss of contractile function
and indicating myocardial stunning. For each of the twelve myocardial segments, percent change
in longitudinal strain relative to baseline was calculated at peak HD and post HD. Of the twelve
myocardial segments, those with greater than twenty percent reduction in longitudinal strain
change from baseline were considered to have experienced RWMAs. For each participant, the
number of segments experiencing RWMAs at the peak HD and post HD timepoints were counted.

2.2.11

Statistical Analysis

All statistical analyses presented in this paper were performed in GraphPad Prism 9
software (GraphPad Software, La Jolla, California, United States of America).
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2.2.11.1 Participant Demographics and Dialysis Treatment Information
Demographic and dialysis treatment information for the thirteen participants are
summarized with descriptive statistics (minimum value, maximum value, mean and standard
deviation) in Tables 1 and 2.

2.2.11.2 Assessment of Hemodynamic Stability
Hemodynamic stability was assessed using systolic blood pressure measurements. Systolic
blood pressure measurements acquired at baseline, peak HD stress, and post HD were analyzed
using a repeated measure one-way ANOVA. The Geisser-Greenhouse correction was applied to
correct for the sphericity of the data. Pos-hoc testing was completed with Tukey’s correction for
multiple comparison to determine differences in systolic blood pressure between the intradialytic
timepoints.
To determine differences in systolic blood pressure between the CAD+ and CAD- arm,
grouped analysis was performed. A repeated measure two-way ANOVA with group (stenosed or
non-stenosed), timepoint (baseline, peak HD, or post HD), and group-by-timepoint as fixed effects
was performed for the systolic blood pressure measurements. A Geisser-Greenhouse correction
was applied. If any of the fixed effects were statistically significant, post-hoc tests were performed
with Sidak’s correction for multiple comparisons to determine systolic blood pressure differences
between intradialytic timepoints and between groups.

2.2.11.3 Laboratory Testing
Intradialytic changes in electrolyte concentrations measured from the blood samples were
assessed using linear mixed models. Specifically, levels of ionized calcium, sodium, potassium,
chloride, bicarbonate, anion gap, creatinine, and calcium were analyzed using linear mixed models
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with intradialytic timepoint as the fixed effect and participant as the repeated effect. A maximum
likelihood algorithm was used to estimate variance parameters. The Geisser-Greenhouse
correction was applied to correct for the sphericity of the data. If there was a significant effect of
timepoint, post-hoc testing was completed with Tukey’s correction for multiple comparison to
identify differences in electrolyte between timepoints. A linear mixed model was used for these
data, as some participants did not have measures of all electrolytes at all timepoints.
In contrast, intradialytic changes in urea, albumin, magnesium, phosphate, parathyroid
hormone, cardiac troponin T, hemoglobin, C-reactive protein, and hematocrit levels were
measured for all participants at all timepoints. As such, these data were analyzed using repeated
measures one-way ANOVA. The Geisser-Greenhouse correction was applied to correct for the
sphericity of the data. If the ANOVA was statistically significant, post-hoc testing with Tukey’s
correction for multiple comparison was completed to determine differences between timepoints.
Grouped analysis was performed for cardiac troponin T and C-reactive protein
measurements. A repeated measure two-way ANOVA test with intradialytic timepoint and group
(CAD+ or CAD-) as fixed effects were performed with the Geisser-Greenhouse correction for
sphericity. If any fixed effect was statistically significant, post-hoc testing was completed with
Sidak’s correction for multiple comparisons to determine differences between groups and between
timepoints.

2.2.11.4 Global Myocardial Perfusion
First, the global myocardial perfusion values were assessed to identify outliers using the
robust regression and outlier (ROUT) removal method. One participant’s perfusion measurement
of a single timepoint was identified as an outlier and that data point was removed from further
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analysis. The remaining global myocardial perfusion measurements were analyzed using a linear
mixed model with intradialytic timepoint (baseline, peak HD, and post HD) as the fixed effect.
Restricted maximum likelihood estimation was used. If there was a significant effect of
intradialytic timepoint, post-hoc testing with Tukey’s correction for multiple comparisons was
performed to identify the differences in myocardial perfusion between timepoints.
A separate grouped analysis was performed to investigate the effect of CAD on global
myocardial perfusion during dialysis. A linear mixed model with group (CAD+ or CAD-) and
intradialytic timepoint as fixed effects was performed with restricted maximum likelihood
estimation and the Geisser-Greenhouse correction. Post-hoc testing with Tukey’s correction for
multiple comparison was performed to identify differences in myocardial perfusion within and
between groups.

2.2.11.5 Segmental Myocardial Perfusion
Segmental myocardial perfusion measurements from all participants were pooled for
analysis. Myocardial segments perfused by coronary arteries identified with greater than 50%
stenoses were grouped together while myocardial segments perfused by non-stenosed coronary
arteries composed another group. In total, 156 myocardial segments received their blood supply
from normal coronary arteries (‘unaffected’ group) and 39 myocardial segments were supplied by
coronary arteries that had stenosed lesions (‘affected’ group). At each individual timepoint
(baseline, peak HD, post HD), a parametric unpaired two-tailed t-test was performed to determine
statistical significance in myocardial perfusion between the unaffected and affected group.
The number of myocardial segments with greater than thirty percent reduction in perfusion
relative to baseline perfusion values was determined at peak HD and post HD45. A repeated
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measure two-way ANOVA test with intradialytic timepoint and group (CAD+ and CAD-) as fixed
effects was performed with the Geisser-Greenhouse correction for sphericity. If any fixed effect
was statistically significant, post-hoc testing was completed with Sidak’s correction for multiple
comparison to determine differences between groups and between timepoints.

2.2.11.6 Regional Wall Motion Abnormality
The number of myocardial segments experiencing RWMAs was analyzed with a repeated
measure one-way ANOVA. If the ANOVA demonstrated statistical significance, a post-hoc testing
was completed with Tukey’s correction for multiple comparisons to identify differences between
intradialytic timepoints.
Additionally, a grouped analysis was performed to investigate the effect of clinically
significant stenoses on the number of myocardial segments experiencing RWMAs during dialysis.
A repeated measure two-way ANOVA was conducted with group (CAD+ and CAD-) and
intradialytic timepoint as fixed effects and the participant as the repeated effect. A GeisserGreenhouse correction was applied for this analysis. If any of the fixed effects were significant,
post-hoc tests were completed with Tukey’s correction for multiple comparisons to identify
differences in the number of myocardial segments experiencing RWMAs within and between
groups.

2.3 Results
2.3.1 Participants
Of the fourteen participants enrolled, thirteen had a complete set of coronary CT
angiography, dynamic CT perfusion, and echocardiography image data. A coronary CT
angiography image was not successfully acquired for one participant and that participant was
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excluded from all analyses. All thirteen participants included for assessment in this study
completed laboratory testing at baseline, peak HD, and post HD. In our analysis of RWMA, one
participant from the CAD- arm was excluded due to the poor image quality of the echocardiograph.
The participants demographic information reflects the general HD population and is summarized
in Table 2-1.

2.3.2 Dialysis Treatment
The dialysis treatment is summarized in Table 2-3 and includes weight +gain/-loss, presystolic blood pressure (SBP), pre-diastolic blood pressure (DBP), SBP nadir, DBP nadir, Kt/V,
minimum relative blood volume (RBV), mean ultrafiltration rate (UFR), mean UFR relative to
pre-HD weight, and total fluid removed during the HD treatment session.
Table 2-3 Intradialytic clinical information
Mean ± SD
Weight +gain/-loss (kg ± SD)
Pre HD SBP (mmHg ± SD)
Pre HD DBP (mmHg ± SD)
SBP nadir (mmHg ± SD)
DBP nadir (mmHg ± SD)
Kt/V ± SD
Min RBV (% ± SD)
Mean UFR (mL/hr ± SD)
Mean UFR/pre weight (mL/kg/hr ± SD)
Total fluid removed (mL± SD)

1.4 ± 0.7
147 ± 20
62 ± 18
103 ± 19
52 ± 14
1.48 ± 0.3
85.0 ± 3.5
666 ± 203
7.57 ± 2.7
2548 ± 816

*SBP = systolic blood pressure; DBP = diastolic blood pressure; RBV = relative blood volume; UFR = ultrafiltration
rate

2.3.3 Laboratory Testing
Electrolytes that were measured at baseline, peak HD, and post HD included sodium,
calcium, potassium, chloride, phosphate, magnesium, and bicarbonate (Table 2-4). Linear mixed
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modelling and post-hoc multiple comparison test demonstrated expected changes in sodium,
potassium, chloride, bicarbonate, and calcium resulting from dialysis (Supplementary Figure 2-1,
Panel B, C, D, E, and J, respectively). Repeated measure one-way ANOVA and post-hoc testing
showed expected decrease in levels of potassium and magnesium electrolytes with dialysis.
(Supplementary Figure 2-1, Panel C and K, respectively). Similarly, analyses of serum creatinine
and urea displayed decrease in concentration of these electrolytes due to dialysis (Supplementary
Figure 2-1, Panel G and H, respectively). Repeated measure one-way ANOVA test showed a
significant intradialytic change in hemoglobin levels (F(1.686, 20.23)=19.91, p < 0.0001,
Supplementary Figure 2-1, Panel O), Post-hoc testing showed that hemoglobin increased
significantly from the start of dialysis to peak HD stress (100.9 ± 9.4 to 110.9 g/L ± 11.1, p =
0.0002), followed by a decrease at post HD (107.4 ± 10.6 g/L, p = 0.03), while remaining elevated
compared to the start of dialysis (p = 0.01).
Table 2-4 Mean plasma electrolyte concentration of those with significant changes as a response
to hemodialysis treatment
Electrolyte (Conc. ± SD)
Ionized Calcium (mmol/L)
Potassium (mmol/L)
Bicarbonate (mmol/L)
Anion Gap (mmol/L)
Creatinine (umol/L)
Urea (mmol/L)
Albumin (g/L)
Calcium (mmol/L)
Magnesium (mmol/L)
Phosphate (mmol/L)
Hemoglobin (g/L)
C-Reactive Protein (mg/L)
Hematocrit (L/L)

Control (n=13)
Baseline
Peak HD
1.09± 0.1
1.05 ± 0.1
4.62 ± 0.8
3.33 ± 0.4
24.5 ± 2.5
30.1 ± 2.2
16.0 ± 3.7
12.6 ± 2.5
732 ± 190
260 ± 86
18.0 ± 4.7
5.06 ± 1.6
36.3 ± 3.8
41.5 ± 4.6
2.25 ± 0.3
2.28 ± 0.2
1.07 ± 0.2
0.94 ± 0.2
1.77 ± 0.5
0.71 ± 0.1
101 ± 9.4
111 ± 11
10.2 ± 10.1 11.5 ± 11.2
0.31 ± 0.03 0.34 ± 0.04
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Post HD
1.04 ± 0.1
3.35 ± 0.4
30.1 ± 2.1
12.1 ± 2.5
254 ± 98
4.85 ± 1.7
40.1 ± 4.6
2.21 ± 0.2
0.92 ± 0.2
0.78 ± 0.2
107 ± 11
11.0 ± 10.8
0.33 ± 0.03

Biomarkers of cardiac injury and inflammation analyzed were cardiac troponin T (cTnT)
and C-reactive protein (CRP). A one-way ANOVA analysis did not show a statically significant
effect of timepoints on the levels of cTnT (F (1.019, 12.22) = 3.178, p=0.09, Supplementary Figure
2-1, Panel N). Two-way ANOVA analysis with group designation (CAD+ and CAD-) as fixed
effect revealed a significant group effect (F (1,11) = 18.34, p = 0.0013, Figure 2-1A), but no
significant effect of timepoint were seen (F (1.023, 11.25) = 0.5215, p = 0.4889). Post-hoc testing
showed increased cTnT signal in the CAD+ group relative to CAD- group at peak HD (t (2.755) =
4.485, p = 0.0723) and post HD (t (2.605) = 4.434, p = 0.0831) timepoints.
In the thirteen participants, a one-way ANOVA analysis showed a statistically significant
effect of timepoint on levels of CRP (F (1.407, 16.88) = 13.75, p = 0.0008, Supplementary Figure
2-1, Panel P). Post-hoc testing showed that the levels of CRP were significantly higher at peak HD
(11.5 ± 11.2 mg/L) compared to baseline (10.2 ± 10.1 mg/L, p = 0.0041) that remained elevated
post HD relative to baseline (11.0 ± 10.7 vs. 10.2 ± 10.1 mg/L, p = 0.011). Two-way ANOVA
analysis with group designation (CAD+ and CAD-) as a fixed effect revealed a significant effect
of timepoint (F (1.441, 15.85) = 12.95, p = 0.0011, Figure 2-1B), but no significant group effect
(F (1, 11) = 1.677, p = 0.2218). Post-hoc testing showed an increase in CRP level from baseline to
peak HD (8.3 ± 7.2 vs. 9.4 ± 8.1 mg/L, p = 0.0167) that remained elevated post HD in the CADgroup, although insignificant (9.0 ± 7.7 mg/L, p = 0.0671).
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Figure 2-1 Mean cardiac troponin T (panel A) and C-reactive protein (panel B) in CAD- (n=10)
and CAD+ arm (n=3) at baseline, peak HD stress, and post HD. Error bars represent the standard
error of the mean. * Denote p < 0.0332.

2.3.4 Systolic Blood Pressure for Hemodynamic Stability
The repeated measure one-way ANOVA demonstrated a significant effect of timepoint (F
(1.614, 19.3) = 8.963, p = 0.003). The post-hoc testing showed that systolic blood pressure was
significantly lower at peak HD in comparison to baseline (119.5 ± 24.15 mmHg vs. 145.2 ± 24.92
mmHg, p = 0.019, Figure 2-2). Systolic blood pressure post HD (121.9 ± 21.70 mmHg), was not
significantly different from peak HD (p = 0.886) but was significantly reduced relative to baseline
(p = 0.012).
In the grouped analysis with the CAD+ and CAD- arms, two-way ANOVA showed a
significant effect of intradialytic timepoint (F (1.523, 16.75) = 5.161, p = 0.0246). Post-hoc testing
revealed no differences in systolic blood pressure between the CAD+ and CAD- groups at
individual HD timepoints. However, only the CAD- group demonstrated a statistically significant
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reduction in mean systolic pressure at peak HD (p = 0.0362, Figure 2-3) relative to baseline,
followed by a partial recovery to baseline values at post HD (p = 0.0727, Figure 2-3).
✱
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Figure 2-2 Mean systolic blood pressure (n=13) at baseline, peak HD stress, and post HD. Error
bars represent the standard error of the mean. * Denote p < 0.0332.
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Figure 2-3 Mean systolic blood pressure in CAD- (n=10) and CAD+ arm (n=3) at baseline, peak
HD stress, and post HD. Error bars represent the standard error of the mean. Solid significance bar
is based on the post hoc test performed on the non-stenosed group. * Denote p < 0.0332.

2.3.5 Coronary Artery Status
Coronary angiography findings of the thirteen participants are summarized in Table 2-5.
Of the thirteen participants, three were identified to have multivessel CAD with stenoses greater
than fifty percent. The LCx artery was identified to be the most commonly stenosed in this
participant group. One CAD+ participant had stenosed lesions in all three of the coronary arteries
and was also evaluated with a high calcification score. Ten participants showed no
hemodynamically significant lesions that were greater than fifty percent stenosed and one of the
participants in this group had high calcification scoring. In total, thirty-nine coronary arteries were
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imaged across thirteen participants. Of these, three were not evaluable due to poor image quality
and were removed from further analysis. Amongst the three participants with CAD, seven coronary
arteries had stenosed lesions with potential for hemodynamic significance (2 RCA, 2 LAD, 3 LCx).
Table 2-5 Descriptive analysis of coronary artery status of individual patients. (+) denote lesions
with > 50 % stenoses in the respective coronary artery and (-) indicate no stenosed lesions or
stenosis ≤ 50 %.
Participant #
1
2
3
4
5
6
7
8
9
10
11
12
13
Total Lesions (%)

RCA
NE
+
+
NE
15

LAD
+
+
NE
15

LCx
+
+
+
23

Highly Calcified
+
+
15

*RCA = right coronary artery; LAD = left anterior descending artery; LCx = left circumflex artery; NE = not evaluable

2.3.6 Global Myocardial Perfusion
Linear mixed modelling revealed a statistically significant fixed effect of timepoint (Figure
2-4, p = 0.0115). Post-hoc testing showed that global myocardial perfusion was significantly lower
at peak HD compared to baseline (79.18 ± 21.00 ml/min/100g vs. 94.14 ± 18.01 ml/min/100g, p =
0.0001) before normalizing back to baseline levels at post HD (90.35 ± 17.76 ml/min/100g, p =
0.37, Figure 2-4). When including the group designation (CAD+ vs. CAD-) in the linear mixed
model, there were no significant effect of group (F (1,11) = 0.021, p = 0.8874). However, there
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was a trend towards an effect of timepoint (F (1.416,14.86) = 3.375, p = 0.07). Figure 2-5
qualitatively demonstrates the effect of timepoint on a single participant. Post-hoc multiple
comparison testing showed a reduction in global myocardial perfusion in the CAD- participant
group from baseline to peak HD (97.25 ± 18.13 ml/min/100g vs. 78.65 ± 17.89 ml/min/100g, p
<0.0001, Figure 2-6), and perfusion recovery from peak HD to post HD (78.65 ± 17.89
ml/min/100g vs. 94.81 ± 16.49 ml/min/100g, p = 0.0029, Figure 2-6). There were no significant
changes in intradialytic global myocardial perfusion measurements in the CAD+ participant group

Global Myocardial Perfusion (ml/min/100g)

(Figure 6).

110

ns
ns

✱✱✱
100

90

80

70

Baseline
Peak HD
Post HD
Figure 2-4 Mean global myocardial perfusion in all participants (n=13) at baseline, peak HD

stress, and post HD. Error bars represent the standard error of the mean. *** Denote p < 0.0002.
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Figure 2-5 Qualitative assessment of changes in myocardial perfusion through dialysis of a single
participant, in the absence of coronary artery stenosis. Cardiac image in of a short axis view and
the regions outlined in white and identifiable by the white arrows represent myocardial regions

Global Myocardial Perfusion (ml/min/100g)

with perfusion reduction.

200
✱✱✱✱
150

✱✱

100

CAD CAD +

50
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Figure 2-6 Mean global myocardial perfusion in CAD- (n=10) and CAD+ (n=3) participants. Error
bars represent the standard error of the mean. Significance bar for pairwise comparison reflect that
within the non-stenosed group. ** Denote p < 0.0021 and **** denote p < 0.0001.
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2.3.7 Segmental Myocardial Perfusion
At baseline (Figure 2-7A), the segmental myocardial perfusion measurements were not
significantly different between the affected and unaffected group (t (193) = 1.587, p = 0.1142).
Similarly, the segmental perfusion measurements were not different between groups at peak HD
(Figure 2-7B, t (193) = 0.9012, p = 0.369). However, at post HD timepoint (Figure 2-7C), the
mean segmental myocardial perfusion in the affected group was significantly lower compared to
the unaffected group (70.02 ± 21.59 ml/min/100g vs. 92.19 ± 39.48 ml/min/100g, t (193) = 3.380,
p = 0.0009).
The number of myocardial segments with greater than thirty percent reduction in perfusion
were quantified (Figure 2-8). Two-way ANOVA showed no significance in the interaction
between timepoint and group (F (1, 11) = 0.2362, p = 0.6365). There was a signal for an effect of
intradialytic timepoint (F (1,11) = 4.217, p = 0.0646), warranting further testing. Post-hoc testing
showed that fewer myocardial segments experienced greater than thirty percent reduction in
perfusion at post HD compared to peak HD in CAD- participant group (p = 0.045). In participants
with CAD+, no statistical difference between the timepoints was seen (p = 0.629).
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Figure 2-7 Mean myocardial perfusion in unaffected segments (n=156) and affected segments
(n=39) at (A) baseline, (B) peak HD stress, and (C) post HD. Error bars represent the standard
error of the mean. *** Denote significance of p < 0.0002.
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Figure 2-8 Mean number of myocardial segments with greater than 30% reduction in myocardial
perfusion at peak HD stress and post HD relative to baseline myocardial perfusion. Error bars
represent standard error of the mean. * Denote p < 0.0332.

2.3.8 Regional Wall Motion Abnormality
In the twelve participants with viable echocardiography data, one-way ANOVA analysis
showed a statistically significant effect of timepoint on the number of myocardial segments
experiencing RWMAs (F (1.875,20.62) = 31.16, p = 0.0115, Figure 2-9). Post-hoc testing showed
that the number of segments experiencing RWMAs were significantly higher at peak HD
compared to baseline (5.5 ± 2.9 segments, p = 0.0001). This remained elevated at post HD relative
to baseline (4.7 ± 2.6 segments, p = 0.0002). Two-way ANOVA analysis with group designation
(CAD+ vs. CAD-) as a fixed effect revealed a significant effect of timepoint (F (1.844,18.44) =
28.67, p < 0.0001), but no significant group effect (F (1,10) = 1.717, p = 0.2193, Figure 2-10).
Post-hoc testing showed an increase in segments experiencing RWMAs in the CAD- participant
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group from baseline to peak HD (5.1 ± 3.2 segments, p = 0.003), that is reduced post HD compared
to at peak HD (4.0 ± 2.5 segments, p = 0.003). In the CAD+ group, there was a similar increase in
segments experiencing RWMAs at peak HD (6.7 ± 1.5 segments, p = 0.031). A trend towards
increased segments experiencing RWMA at post HD relative to baseline (6.7 ± 2.1 segments, p =
0.056) was also detected for the CAD+ group.
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Figure 2-9 Mean myocardial segments with regional wall motion abnormalities (n=12). Error bars
represent the standard error of the mean. *** Denote p < 0.0002.

79

RWMA (# of segments)

12
10

✱✱

✱✱
✱

8
6
4
2

CAD -

0

CAD +
Baseline

Peak HD

Post HD

Figure 2-10 Mean regional wall motion abnormality in CAD- (n=9) and CAD+ (n=3) participants.
Error bars represent the standard error of the mean. Solid significance bars for pairwise comparison
performed in the non-stenosed group. Dotted significance bar for pairwise comparison completed
for the stenosed arm. * Denote p < 0.0332 and ** denote p < 0.0021.

2.4 Discussion
This study demonstrated HD-induced circulatory stress as measured by a reduction in
myocardial perfusion and elevation in myocardial stunning that was independent of CAD. In our
study population, where none of the patients had symptomatic CAD, it was revealed that almost a
quarter of this population had considerable plaque burden that were flow limiting. These flowlimiting stenoses exacerbated perfusion anomalies in myocardial segments to which it supplied
blood, leading to myocardial stunning that could not be recuperated following the end of HD
treatment.
Participant without CAD experienced a significant rise in myocardial stunning during HD
treatment which appears to be related to the reduction in myocardial perfusion. This is in line with
previous findings from our lab as well as others, demonstrating intradialytic reduction in organ
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perfusion during HD. Marants et al. conducted an intradialytic CT perfusion study to explore HD
effects on renal perfusion, and was able to show acute decrease in renal perfusion during HD
treatment48. Many studies looked into the effects of HD on the brain and similarly concluded that
HD induced reduction in cerebral blood flow. This was confirmed using transcranial doppler, CT,
magnetic resonance imaging, and near infrared spectroscopy49–54. As all vascular beds originate
from a single contiguous endothelial surface, it is expected that during an ischemic insult such as
the one experienced during HD, the reduction in blood flow occurs in multiple vascular beds. The
heart is also a vascular bed that experiences HD ischemic injury. McIntyre et al. demonstrated a
reduction in regional myocardial perfusion throughout dialysis using positron emission
tomography, with its lowest mean perfusion measurement at four hours from commencing
dialysis45. They also determined that myocardial segments identified to have RWMAs were
significantly associated with greater reduction in myocardial perfusion from baseline compared to
normal segments45. This study also identified a greater than thirty percent reduction in perfusion
from baseline as the perfusion threshold associated with regional wall motion abnormality45. It is
evident from our current study that with HD, there is a general reduction in global myocardial
perfusion and an increased number of myocardial segments experiencing regional wall motion
abnormality or myocardial stunning in participants with no CAD. Shortly after the end of HD
treatment, global myocardial perfusion is recovered and stunned myocardial segments are partially
salvaged upon reperfusion.
The addition of CAD appears to be associated with worsened response to HD treatment as
evidenced by the consistently hypoperfused myocardium and prolong stunning that does not
recover following the end of HD treatment. We have shown that unlike the traditional perfusion
response seen with HD, participants with CAD showed no intradialytic perfusion changes,
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however, the mean perfusion measurements tended to be lower at baseline and post HD timepoint
compared to those without known CAD. The modest level of global myocardial perfusion in the
CAD+ arm at baseline may be the result of the flow limiting epicardial artery stenoses that have
been identified through coronary angiography. In all intradialytic timepoints, myocardial segments
corresponding to coronary arteries with stenosed lesions greater than fifty percent demonstrated
trends of lower perfusion, indicating that these identified stenoses were in fact flow-limiting. The
reduction in perfusion in the myocardial segment affected by CAD was most evident after the end
of HD treatment. This suggests that reperfusion of these segments affected my flow-limited
stenoses may take longer to return to baseline perfusion levels, which is also evident through the
lack of improvement in the number of myocardial segments with greater than 30% reduction in
perfusion in CAD+ arm. With this in mind, it is interesting to see that with the extended duration
of ischemic-reperfusion injury associated with CAD, the number of stunned myocardial segments
remained elevated and persistent from peak HD to post HD. These findings suggest that the CAD
plays a significant role in the recovery phase of HD treatment (post HD).
The two laboratory measurements that have been important predictors of CAD in HD
patients include cTnT and CRP. A rise in cTnT has been used as a marker of myocardial cell injury
in clinically suspected myocardial ischemia55. There continues to be controversy regarding the
clinical usefulness of measuring cardiac troponin levels to diagnosis acute ischemic injury
continues in the chronic HD population, as its levels are frequently higher at baseline without
evidence of injury56–64. In our current study, there were no evident intradialytic changes in mean
cTnT levels in the thirteen HD participants, despite its higher-than-normal levels. The three
participants with CAD showed trends of increased cTnT at baseline relative to the CAD- arm, that
remained higher at peak HD and post HD timepoints. The elevated levels of cTnT at baseline in

82

the CAD+ arm may represent the existence of a prior silent infarct or subclinical myocardial
ischemia where the stenoses constructs the delivery of blood and ultimately, oxygen to the
myocardial cells, causing injury. The presence of a coronary stenoses may potentially have an
additive effect on cTnT levels in those with chronic HD. The lack of change in troponin levels
throughout dialysis in the CAD+ arm may be a response to the increased ischemia experienced in
these participants when HD-induced and stenoses effects are combined.
In a study completed on a HD population, it was concluded that the probability of
cardiovascular disease almost doubles when the serum CRP levels are greater than 0.6md/dL65.
CRP shows trends of higher concentration in the blood stream of the CAD+ group than the nonstenosed. Generally, CRP > 3.0mg/L is a major risk factor for heart disease66. In this study, the
mean CRP levels at baseline was greater than 3.0 mg/L in HD with no CAD. This elevation in
CRP in CAD- HD participant can be a result of the chronic inflammation associated with HD, that
is most evident with significant intradialytic changes in CRP. The mean CRP levels are
approximately doubled in participants on HD with CAD. CRP levels has shown to be a possible
biomarker of vascular inflammation in coronary artery disease67–69. The excessive levels of CRP
we see in the CAD+ arm may be an indication of vascular inflammation and vessel damage
localized to the affected artery.
This study was a retrospective exploratory study with a limited number of HD participants;
data should be interpreted with this in mind. Despite the small number of participants, the effect
sizes of the reported results in the present study are large. Cohen’s d was calculated for the primary
outcomes of global myocardial perfusion and RMWAs. The calculated Cohen’s d value for global
myocardial perfusion between the two arms at baseline, peak HD, and post HD were 1.38, 0.08,
and 1.21, respectively. The calculated Cohen’s d value for regional wall motion abnormality
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between the two arms at peak HD and post HD were 0.62 and 1.16, respectively. Generally, a
Cohen’s d value greater than 0.8 is considered to be a large effect size. While the number of
patients studied was small, it was able to demonstrate the circulatory and function cardiac changes
to HD with respect to the coronary artery health. It is important to also note that as a result of the
small sample size, it is unlikely that other variables presented in this work were powered to detect
change.

2.5 Conclusion
HD treatment induces ischemic injury to the heart causing myocardial stunning that is not
specific to the presence or absence of CAD. In a limited number of participants with no clinical
evidence or symptoms of CAD, this study has shown that the cardiac response (perfusion and
stunning) to HD is exacerbated with the addition of stenosed lesions in the coronary artery. Patients
with severe and unresolved intradialytic stunning may warrant screening for CAD with CT
angiography for intervention to improve tolerability of HD treatment. Further work is required,
and we acknowledge that a larger randomized clinical trial would be beneficial in providing a
complete summary of varying degrees of CVD on patient’s cardiac response to HD. This would
further allow personalized treatment methods for patients undergoing HD.
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Chapter 3

3 The effect of dialysate sodium on endothelial injury and
microcirculatory dysfunction
A version of this chapter is in preparation for publication: Lisa Hur, Yanmin Zhang, Barry
Janssen, Christopher W. McIntyre, “The effect of dialysate sodium on endothelial injury and
microcirculatory dysfunction,” In preparation. Aug 2022.
Abstract Each episode of hemodialysis (HD) treatment causes injury to the glycocalyx which
induces shedding of syndecan-1 (syn-1), a transmembrane heparan sulfate proteoglycan. This
damage results from hemodynamic stress of HD itself and injury caused by oncotic shifts in the
presence of additional sodium (Na+) during HD. The glycocalyx binds Na+, buffering sudden
serum Na+ shifts, and can be damaged with acute changes in Na+ concentration. The aim of this
study is to use a preclinical platform to investigate the effects of Na+ dialysate concentration on
endothelial cell injury and microcirculatory dysfunction during HD. We hypothesize that changes
in plasma Na+ concentration will result in the direct injury to the glycocalyx and reduce
microcirculatory perfusion. Twenty-seven healthy male Wistar Kyoto rats underwent HD: eight
were exposed to dialysate Na+ concentration at typical rat plasma Na+ level (isonatric, 140mM),
ten were exposed to dialysate Na+ below typical rat plasma Na+ level (hyponatremic, 130mM),
and nine were exposed to dialysate Na+ above typical rat plasma Na+ level (hypernatremic,
150mM). Throughout HD, intravital microscopy (IVM) was used to image the microvasculature
at baseline, during extracorporeal circulation with no dialysate flow (“Sham”), at 1 hr into HD, at
2 hrs into HD, and post HD (“Final”). The IVM images were processed to derive the number of
identified intersecting points, a metric quantifying microcirculatory blood flow, to observe the
change in perfusion index at each timepoint. Blood samples were collected at the same timepoints
corresponding to the IVM image acquisitions to measure syn-1 and quantify glycocalyx shedding
during HD. Blood pressure of the animal were acquired continually throughout the experiment.
Blood pressure between the three groups were comparable. The findings demonstrate a gradual
increase in syn-1 concentration in blood plasma throughout the duration of the experiment in the
isonatric, hyponatremic, and the hypernatremic groups. The percent change in syn-1 of the
hypernatremic group doubled that of the isonatric and hyponatremic group by 2hrs into HD. The
experimental groups demonstrated a consistent trend of lower perfusion index throughout the
duration of the experiment. A single HD session can possibly elevate syn-1 and reduce
microvascular perfusion, indicating HD-associated endothelial injury and microcirculatory
dysfunction. As well, the damage to the glycocalyx may be more pronounced with hypernatremic
effects.
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3.1 Introduction
The therapeutic aim of hemodialysis (HD) is to artificially remove the interdialytic sodium
load accumulated between dialysis sessions that cannot be eliminated efficiently by the kidney in
individuals with end stage renal disease (ESRD). Failure to effectively remove sodium from the
body results in interdialytic fluid gain, hypertension and exacerbated ischemic injury as a result of
the unfavorably high ultrafiltration requirement to achieve target weight1–5. This can be explained
by the need to intake fluid to maintain sodium-water balance in our body after the ingestion of
sodium rich content which in turn increases interdialytic weight gain. Furthermore, sodium that
was not cleared through dialysis is deposited in the skin and muscle (including the myocardium)6;
the storage capacity of sodium in the tissue is limited and the buffer capacity of the vasculature for
interdialytic circulating serum sodium is variable amongst individuals7. Excess serum sodium
concentration directly results in injury to the endothelial glycocalyx (discussed below) and
aggravates ischemic vulnerability to the circulatory stress induced during HD. However, excessive
sodium depuration during HD could cause hypotension and circulatory collapse owing to the lack
of maintenance of plasma tonicity and refill.
Currently, the manipulation of dialysate sodium concentration is the principle approach in
achieving sodium homeostasis in HD patients. Low dialysate sodium concentration has been
shown to reduce sodium deposition in the tissue using sodium MR imaging while minimizing
interdialytic weight gain6. Despite these advantages of low dialysate sodium concentration, sodium
dialysate concentration cannot be prescribed as a one size fits all approach. As discussed earlier,
one of the detrimental effects of low sodium is hypotension and circulatory collapse; patients
predisposed to these symptoms would experience worsening HD-associated cardiovascular injury
when treated with low sodium dialysate concentration. Hence, it is difficult to determine the most
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optimal dialysate sodium concentration based on the limitations in our knowledge relating to the
mechanism of HD-induced circulatory dysfunction in the presence of sodium. One of the common
non-invasive methods of assessing tolerability to HD treatment is through quantification of
myocardial stunning, a surrogate marker of regional ischemia8–14. The observed variation in
myocardial stunning during HD is mostly attributed to factors relating to hemodynamic stress
including hypovolemia, hypotension, tissue ischemia, and arrythmias15. Investigation of other nonhemodynamic stress factors such as osmotic shift and changes in electrolyte may potentially shed
light on other approaches to improving tolerability to HD treatment.
The recent findings of endothelial damage with acute rise of plasma sodium during dialysis raised
the possibility that investigation of sodium may be important16. Syndecan-1 is a transmembrane
heparan sulfate proteoglycan and a component of the glycocalyx layer on the luminal side of the
endothelial cell17. With endothelial dysfunction, syndecan-1 sheds from the cell surface into the
bloodstream. Consequences of a damaged endothelium include the loss of vascular integrity (i.e.
inability to control dilation and constriction) and increases in vascular permeability18,19. The earlier
study investigating changes in plasma sodium during HD suggested that the stability of the
endothelium was influenced by the plasma sodium concentration exceeding the buffering capacity
of the glycocalyx. The hemodynamic stress of HD itself in addition to the injury caused by the
acute oncotic shift in the presence of excess sodium during HD may explain the endothelial
vulnerability and damage seen in the HD population. With damage to the endothelium, we expect
to consequently see dysfunction in the vasculature. Microvascular dysfunction results in the
maldistribution of blood flow or irregular microcirculation within arterioles, venules, and
capillaries20. This transpires with maintenance HD treatment; there is inadequate perfusion to the
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tissue due to microvascular dysfunction, causing irreversible ischemic damage and reaching organ
failure with time 21–24.
The question we aim to address in this research paper is whether or not sodium is a contributor of
HD-induced endothelial injury, making the patient more vulnerable to microvascular dysfunction
and ischemia. Our lab has previously created a small-animal hemodialysis system to study the
effect of hemodialysis on the microcirculation in a small animal model24. Using intravital video
microscopy on surgically exposed muscle tissue, changes in microvascular blood flow were
measured and quantified while the animal was be dialyzed. The purpose of this current study was
to use this established preclinical model to investigate the effects of sodium dialysate concentration
on endothelial cell injury and microcirculatory dysfunction during HD. It is hypothesized that
changes in plasma sodium concentration will result in the direct injury to the glycocalyx, affecting
the degree of microcirculatory perfusion during HD.

3.2 Methods
3.2.1 Experimental Animals
The experiments conducted in this study followed the Canadian Council of Animal Care
and the ARRIVE guidelines and regulations. This work has been approved by the Animal Care
and Use Committee of Western University (London, Ontario Canada).
Thirty-one male Wistar-Kyoto rats (approximately 250 – 300g in weight, SPF, Charles
River, Wilmington, MA, United States of America) were group-housed in standard conditions, at
room temperature. The animals were fed without restriction and were exposed to 12-hour periods
of light-dark cycle per day. Interaction with cage-mates were unrestricted. Upon arrival from the
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supplier, animals had a minimum of 72 hours to acclimatize to the new environment before
proceeding with experiment procedures.

3.2.2 Surgical Procedure for Muscle Microvasculature Imaging
Prior to muscular surgery, the animals were anaesthetized with a mixture of four percent
isoflurane and one percent oxygen. To ensure the maintenance of anesthesia while minimizing its
effect on blood pressure, two percent isoflurane was delivered continuously through a facemask
ventilator fitted for small animals. A rectal temperature probe was used for continuous monitoring
of the core body temperature throughout experimental procedure (TCAT-2 Temperature
Controller, Physitemp Instruments LLC, Clifton, NJ, United States of America). The body
temperature was maintained at 36.5°C with an infrared lamp. For continuous monitoring of the
animal blood pressure, a catheter was inserted into the carotid artery and connected to a pressure
transducer that measured the mean arterial blood pressure and heart rate (DMSI-400, Micro-Med
INC, Louisville, Kentucky, United States of America). Heparinized dialysate (2U/mL) was used
periodically to ensure the carotid artery catheter did not occlude.
The extensor digitorum longus (EDL) muscle of the animal’s right hind leg was exposed
for intravital microscopy according to the surgical procedure outlined by Tyml and Budreau25.
After the exposure, the EDL muscle was left open to air for thirty minutes prior to the visualization
of the circulation under the intravital microscopy. Microvascular perfusion behaviors were
observed using an inverted microscope (Nikon Eclipse-Ti, Nikon Instruments, Melville, New
York, United States of America) with a modified microscope stage, a 100-watt xenon light source
(PTI LPS 220, Horiba Scientific, Piscataway, New Jersey, United States of America) and an
optical light guide (Thorlabs, Newton, New Jersey, United States of America). To prevent tissue
damage, a 400-550nm bandpass filter was used to restrict the frequencies of light used for tissue
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imaging. For better visualization of the red blood cells, an additional 450nm/20nm bandpass filter
was placed directly on the camera.

3.2.3 Small-Animal Dialyzer Unit
The small-animal dialyzer units used in this study were assembled in-house using 75 fiber
parts of an existing conventional polysulphone dialyzer (FX 600 Helixone, Fresenius, Canada).
Following the designs of the dialyzers utilized clinically, the fibers were encapsulated in a
polycarbonate tube (Figure 3-1). The internal volume of the microdialyzer was 290µL. The
dialyzer had an external bypass line connected from one end to the other, holding the equivalent
volume of fluid as the dialyzer itself, and enabling study of the effects of the change in systemic
blood volume that occurs during dialysis but in the absence of dialysate flow.

Figure 3-1 Small animal dialysis unit

3.2.4 Dialysate Composition
To study the effects of dialysate sodium concentration on the microvasculature, fresh
dialysate fluid of specific sodium concentration was prepared for each experiment. The first group
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was the isonatric (control) group; animals in this arm were exposed to dialysate fluid of 140mM
sodium concentration that is comparable to their baseline plasma sodium level. The second was
the hyponatremic group, whose dialysate fluid was of lower sodium concentration (130mM).
Lastly, the third arm was the hypernatremic group, exposed to high levels of sodium (150mM). To
assess accuracy of the dialysate prescription, samples of the dialysate fluid were collected, and
levels of sodium were measured. The dialysate sodium concentration for the isonatric group were
determined based on our previous rodent study that showed plasma sodium concentration ranging
between 139 and 140 mmol/L at baseline24. To ensure variability in the delivered sodium dialysate
concentration, the sodium concentration chosen for the hypo- and hypernatremic group were ± 10
mM of the isonatric group.

3.2.5 In-vivo Hemodialysis Experiment
In the left hind limb, the limb without EDL muscle exposure, two catheters were inserted
to establish extracorporeal blood flow (Figure 3-2). A catheter was placed in the left femoral artery
for blood outflow to the dialyzer, and a second catheter was inserted within the left femoral vein
for the return of filtered blood from the dialyzer to the systemic circulation of the animal. The
catheters were securely connected to the dialyzer, and the extracorporeal circulation of blood was
initiated using a peristaltic pump (P720, Instech Lab., Plymouth Meeting, Pennsylvania, United
States of America). Immediately after initiation, ‘baseline’ blood samples and intravital
microscopy images were acquired. The blood was then circulated through the dialysis circuit for
one hour. After one hour, blood samples and intravital microscopy images were collected for the
‘sham’ timepoint. Subsequently, the blood flow was directed to pump through the dialyzer for two
hours at a rate of 2ml/kg/hr. For dialysate flow, two peristaltic infusion pumps (Sigma Spectrum
V8 Infusion System, Baxter, Deerfield, Illinois, United States of America) were used at 1ml/min,
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with continuous adjustment throughout the experiment depending on the hematocrit level. Blood
samples and intravital microscopy images were repeated at 1hr and 2hrs into HD treatment.

Figure 3-2 Small animal hemodialysis experimental set-up

3.2.6 Acquisition of Experimental Blood Work
At baseline, sham, 1hr HD, and 2hr HD, 200µL of blood were sampled from the animals,
directly through the dialyzer unit. Of the 200µL, 100µL of the sample was added to the iStat EC8+
cartridge (Abbot, Princeton, New Jersey, United States of America) for analysis of sodium,
potassium, chloride, glucose, blood urea nitrogen, hematocrit and hemoglobin levels. Creatinine
levels were measured with the remaining blood sample (100µL) with the iStat Crea cartridge
(Abbot, Princeton, New Jersey, United States of America). The cartridges were processed using a
VetStat point of care blood gas analyzer (VetScan i-STAT-1 Handheld Analyzer, Abaxis, Union
City, California, United States of America.
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3.2.7 Intravital Microscopy: Quantification of Microvascular Perfusion
The acquisition of the dynamic (sequence of 60 seconds at 30 frames per second)
microvascular perfusion images at baseline, sham, 1hr HD, and 2hr HD were completed using a
multispectral multicamera system (MSMC-23-1-A, Spectral Device Inc., London, Canada). At
baseline, multiple adjacent fields of views are selected for recording. In the subsequent imaging
timepoints, the microvascular perfusion of previously selected fields of views are acquired,
allowing the quantification of the observed change in microvascular perfusion throughout the
experiment.
The intravital images were post-processed using in-house software written in Matlab (Matlab
2020a, the Matworks Inc, Natrick, Massachusetts, United States of America)26,27. The software
applies an algorithm to identify perfused vessels within the field of view captured based on the
active flow of the red blood cells. This is completed by assessing the change in light intensity
caused by the movement of the red blood cell within the pixels of interest. From this information,
a sum of absolute intensity difference image is generated for each field of view at each
experimental imaging timepoints (baseline, sham, 1hr HD, and 2hr HD), allowing the user to
visualize the perfused vessels. An additional processing step follows for the quantification of the
number of perfused vessels: a ten-by-ten grid is mapped onto the sum of absolute intensity
difference image, where a separate two-step machine learning algorithm is applied to identify
points within the grid with observed perfusion. The number of identifiable points of intersection
between the grid and the regions of vessel perfusion are added to represent the perfusion index of
the specific field of view and experiment timepoint.
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3.2.8 Plasma Sampling: Quantification of Syndecan-1
At baseline, sham, 1hr HD, and 2hr HD, 150µL of blood were obtained from the animal,
directly through the dialyzer unit. Shortly after the end of HD, a final set of blood samples were
collected from the animal. This served as the endpoint for the animals. The acquired blood samples
were centrifuged for thirty minutes at 2500 RCF in 4°C to extract the plasma layer. The plasma
samples collected in thirty-one animals were stored in a -80°C freezer before processing. A
commercially available ELISA kit was used to quantify rodent syndecan-1 levels (Novus
Biologicals, NBP2-76611, Littleton, Colorado, United States of America). ELISA experiments
were performed in accordance with the manufacturers’ instruction manual. The reference
standards were within the limits of detection and were fitted to a 4-parameter logistic model. This
model was then used to estimate absolute concentration of syndecan-1. To assess the damage of
the glycocalyx and endothelium, the percent change in syndecan-1 concentration at sham, 1hr HD,
2hr HD, and final were calculated in reference to the baseline.

3.2.9 Statistical Analysis
All statistical analyses described in this section were completed using GraphPad Prism 9
software (GraphPad Software, La Jolla, California, United States of America).

3.2.9.1

Dialysate Composition

Ordinary one-way ANOVA was performed to compare the dialysate sodium levels
between the experimental groups (isonatric, hyponatremic, and hypernatremic). In the case the
one-way ANOVA test demonstrated statistical significance, post-hoc tests were completed with
Tukey’s correction for multiple comparison. The means and standard deviations were also
recorded following a descriptive statistical analysis.

104

3.2.9.2

Experimental Blood Work

Levels of sodium, potassium, chloride, glucose, blood urea nitrogen, creatine, hematocrit,
and hemoglobin were recorded at baseline, sham, 1hr HD, and 2hr HD. For each of these
measurements, a repeated measure two-way ANOVA with group (hyponatremic, isonatric,
hypernatremic) and timepoint (baseline, sham, 1hr HD, 2hr HD) as the fixed effect was performed
to enable comparison between timepoints as well as between experimental groups. A GeisserGreenhouse correction was applied. If a fixed effect was statistically significant, post-hoc testing
was performed with Tukey’s correction for multiple comparison.

3.2.9.3

Mean Arterial Pressure for Assessment of Hemodynamic Stability

Hemodynamic stability throughout the experiment was assessed via continuous monitoring
of mean arterial pressure. The mean arterial pressure was recorded for analysis at baseline, sham,
1hr HD, and 2hr HD. To analyze the mean arterial pressure data between the three experimental
groups across the timepoints, a linear mixed model analysis was completed with group
(hyponatremic, isonatric, hypernatremic) and timepoint (baseline, sham, 1hr HD, 2hr HD) as the
fixed effects. Residual maximum likelihood estimation was used and a Geisser-Greenhouse
correction for sphericity was applied. If a fixed effect was statistically significant, post-hoc testing
with Tukey’s correction for multiple comparison was completed.
In addition, a Pearson correlation analysis was performed on the pooled data of all animals
across at all available timepoints to assess the association between the percent change in syndecan1 measurements and the microvascular perfusion index.
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3.2.9.4

Microvascular Perfusion Index through Intravital Microscopy

The changes in microvascular perfusion index throughout the experiment were analyzed
with a repeated measure two-way ANOVA with timepoints (sham, 1hr HD, 2hr HD) and group
(hyponatremic, isonatric, hypernatremic) as the fixed effects. The Geisser-Greenhouse correction
was applied. If any of the fixed effects were statistically significant, post-hoc testing was
completed with Tukey’s correction for multiple comparisons to identify statistically significant
differences.

3.2.9.5

Syndecan-1 as a Marker of Endothelial Injury

The percent change throughout the experiment of syndecan-1 relative to baseline was
analyzed using a repeated measure two-way ANOVA with group (hyponatremic, isonatric,
hypernatremic) and timepoints (sham, 1hr HD, 2hr HD, final) as the fixed effects. The GeisserGreenhouse correction was applied. If any fixed effect was statistically significant, additional posthoc testing was completed with Tukey’s correction for multiple comparisons to identify
statistically significant differences.
In addition, a Pearson correlation analysis was performed on the pooled data of all animals
across at all available timepoints to assess the association between percent change in syndecan-1
and microvascular perfusion index.

3.3 Results
Of the thirty-one animals, four were excluded from analysis due to death, two from the
isonatric arm and two from the hypernatremic arm. In total, there were eight animals in the
isonatric group, ten animals in the hyponatremic group, and nine animals in the hypernatremic
group.
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3.3.1 Dialysate Composition
Ordinary one-way ANOVA analysis showed a significant effect of group (F (2, 24) = 211.3,
p < 0.0001), indicating statistically significant differences in sodium dialysate composition
between isonatric, hyponatremic, and hypernatremic groups. Post-hoc testing showed the expected
statistically significant differences in sodium levels between the hyponatremic and isonatric (131.6
± 2.0mmol/L vs 139.8 ± 2.6mmol/L, p < 0.0001), isonatric and hypernatremic (139.8 ± 2.6mmol/L
vs. 150.2 ± 1.2, p < 0.0001), and hyponatremic and hypernatremic arms (131.6 ± 2.0mmol/L vs.
150.2 ± 1.2, p < 0.0001). The prescribed sodium dialysate and the actual experimental sodium
dialysate concentration are summarized in Table 3-1.
Table 3-1 Dialysate composition for isonatric, hyponatremic, and hypernatremic experimental
arms. Values represent the mean ± standard deviation. Statistical significance performed to
isonatric group.
Sodium Conc.
(mmol/L)

Isonatric

Hyponatremic

Prescribed

140.0

130.0

Experimental

139.8 ± 2.6

131.6 ± 2.0

p - value

Hypernatremic

p - value

150.0
< 0.0001

150.2 ± 1.2

< 0.0001

3.3.2 Experimental Blood Work
The blood work obtained at baseline, sham, 1 hr HD, and 2 hr HD included serum sodium,
potassium, chloride, glucose, blood urea nitrogen, creatinine, hematocrit and hemoglobin levels.
Repeated two-way ANOVA showed a significant effect of timepoint-by-group effect for both
plasma sodium (F (6,72) = 63.13, p < 0.0001) and chloride (F (6,72) = 113.8, p <0.0001). Posthoc testing showed no differences in plasma sodium and chloride levels between the isonatric,
hyponatremic, and hypernatremic groups at the baseline and sham timepoints (Figure 3-1A,C).
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After 1 hr of commencing HD, the plasma sodium level was significantly different between
groups. Specifically, plasma sodium level was higher in the hypernatremic group (142.4 ± 2.0
mmol/L) and reduced in the hyponatremic group (133.0 ± 0.8 mmol/L), relative to the isonatric
group (p < 0.0001 and p = 0.0004, respectively). At 2 hrs into HD treatment, there remained a
significant difference between the three groups with the mean sodium level remaining elevated in
the hypernatremic group (141.6 ± 2.7 mmol/L, p = 0.0071) and low in the hyponatremic group
(132.6 ± 0.8 mmol/L, p < 0.0001), relative to the isonatric group.
Repeated two-way ANOVA showed no statistically significant group effect for potassium,
glucose, blood urea nitrogen, creatinine, hematocrit, and hemoglobin levels. However, significant
effect in timepoint was revealed in levels of potassium, glucose, blood urea nitrogen creatinine,
hematocrit, and hemoglobin. Table 3-2 reports the results of the post-hoc tests for the isonatric
group over the duration of the experiment. In the standard isonatric arm, the mean potassium
increased from baseline to sham (4.5 ± 0.2 mmol/L vs. 4.7 ± 0.3 mmol/L, p = 0.0375) but was
reduced with 1 hr and 2 hr dialysis compared to baseline values (3.2 ± 0.1 mmol/L, p < 0.0001 and
3.4 ± 0.1 mmol/L, p < 0.0001, respectively). In this group, there was a trend of increasing plasma
glucose from baseline (184 ± 22.4 mg/dL) to sham (197 ± 19.5 mg/dL, p = 0.06), followed by a
significant reduction in glucose at 1 hr and 2 hr after initiating HD relative to baseline
measurements (122 ± 4.6 mg/dL, p = 0.0005 and 106 ± 16.3 mg/dL, p = 0.0005, respectively).
Relative to baseline levels, the blood urea nitrogen was elevated at the time of sham (24.9 ± 2.7
mg/dL, p = 0.0022), but declined at 1 hr HD (10.5 ± 2.2 mg/dL, p = 0.0002) and 2 hr HD (12.9 ±
2.7 mg/dL, p = 0.0038). Similarly, relative to baseline, creatinine levels elevated at the time of
sham (0.49 ± 0.06 mg/dL, p = 0.0068), but declined at 1 hr HD (0.23 ± 0.05 mg/dL, p = 0.0105)
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before recovering to baseline levels at 2 hr HD (0.33 ± 0.14 mg/dL, p = 0.6551). Hematocrit and
hemoglobin levels in the blood were not significantly different throughout the experiment. Similar
changes in blood work were seen in the hyponatremic and hypernatremic groups as summarized
in Table 3-3 and 3-4. These results have been graphically presented in Figure 3-1.
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Table 3-2 Concentration of basic electrolyte at baseline, sham, 1 hr- and 2 hr- into hemodialysis
for to isonatric group (n=8). Values represent the mean ± standard deviation. Statistical
significance test represents comparison of timepoints to the baseline timepoint.
Electrolyte

Baseline

Sham

p
- 1 hr into p
- 2 hr into p
value
HD
value
HD
value

Sodium (mmol/L)

137.8 ± 0.5

137.5 ± 0.5

0.85

137.8 ± 1.4

>0.9999

137.8 ± 1.5

>0.9999

Potassium
(mmol/L)

4.49 ± 0.22

4.74 ± 0.17

0.0375

3.21 ± 0.10

<0.0001

3.39 ± 0.13

<0.0001

Chloride (mmol/L)

97.8 ± 1.75

98.9 ± 1.13

0.0569

92.9 ± 2.2

0.0003

93.1 ± 1.7

0.0005

Glucose (mg/dL)

184 ± 22.4

197 ± 19.5

0.0603

122 ± 4.6

0.0005

106 ± 16.3

0.0005

BUN (mg/dL)

19.4 ± 2.8

24.9 ± 2.7

0.0022

10.5 ± 2.2

0.0002

12.9 ± 2.5

0.0038

Creatinine (mg/dL)

0.38 ± 0.07

0.49 ± 0.06

0.0068

0.23 ± 0.05

0.0105

0.33 ± 0.14

0.6551

Hematocrit
(%PCV)

33.5 ± 2.62

34.8 ± 2.32

0.6388

33.9 ± 4.79

0.9972

32.8 ± 3.45

0.9615

Hemoglobin (g/dL)

11.4 ± 0.89

11.8 ± 0.79

0.6571

11.5 ± 1.64

0.9981

11.1 ± 1.17

0.9572
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Table 3-3 Concentration of basic electrolyte at baseline, sham, 1 hr- and 2 hr- into hemodialysis
for to hyponatremic group (n=10). Values represent the mean ± standard deviation. Statistical
significance test represents comparison of timepoints to the baseline timepoint.
Electrolyte

Baseline

Sham

p
- 1 hr into p
- 2 hr into p
value
HD
value
HD
value

Sodium (mmol/L)

137.5 ± 1.2

137.3 ± 1.2

0.48

133.0 ± 0.8

<0.0001

132.6 ± 0.8

<0.0001

Potassium
(mmol/L)

4.56 ± 0.34

4.92 ± 0.34

0.0062

3.07 ± 0.21

<0.0001

3.20 ± 0.28

<0.0001

Chloride (mmol/L)

97.5 ± 1.90

99.1 ± 1.20

0.0087

87.8 ± 1.03

<0.0001

87.7 ± 1.06

<0.0001

Glucose (mg/dL)

183 ± 28.1

192 ± 26.8

0.2599

118 ± 13.5

<0.0001

98.2 ± 24.6

<0.0001

BUN (mg/dL)

18.8 ± 2.3

24.1 ± 1.7

0.0001

12.0 ± 8.1

0.0646

12.8 ± 3.9

0.0045

Creatinine (mg/dL)

0.39 ± 0.07

0.51 ± 0.11

0.0009

0.28 ± 0.06

0.0141

0.37 ± 0.13

0.9675

Hematocrit
(%PCV)

33.2 ± 3.23

34.2 ± 1.75

0.7128

33.2 ± 1.75

>0.9999

33.3 ± 2.63

0.9997

Hemoglobin (g/dL)

11.3 ± 1.10

11.6 ± 0.48

0.6877

11.3 ± 0.59

>0.9999

11.3 ± 0.89

0.9998
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Table 3-4 Concentration of basic electrolyte at baseline, sham, 1 hr- and 2 hr- into hemodialysis
for to hypernatremic group (n=9). Values represent the mean ± standard deviation. Statistical
significance test represents comparison of timepoints to the baseline timepoint.
Electrolyte

Baseline

Sham

p
- 1 hr into p
- 2 hr into p
value
HD
value
HD
value

Sodium (mmol/L)

137.4 ± 131

136.9 ± 1.6

0.18

142.4 ± 2.0

0.0001

141.6 ± 2.7

0.0074

Potassium (mmol/L)

4.37 ± 0.23

4.52 ± 0.26

0.2047

3.58 ± 0.17

<0.0001

3.78 ± 0.24

0.0014

Chloride (mmol/L)

98.1 ± 0.60

98.9 ± 1.05

0.1542

100.3 ± 1.22

0.0086

101.4 ± 0.88

0.0002

Glucose (mg/dL)

188 ± 22.7

201 ± 19.1

0.0390

133 ± 3.17

0.0003

114 ± 16.0

0.0001

BUN (mg/dL)

18.2 ± 0.8

23.2 ± 2.9

0.0026

13.1 ± 2.7

0.0006

16.2 ± 3.2

0.2252

Creatinine (mg/dL)

0.38 ± 0.07

0.48 ± 0.07

0.0121

0.26 ± 0.05

0.0002

0.41 ± 0.15

0.7538

Hematocrit
(%PCV)

31.8 ± 2.39

33.9 ± 1.69

0.0186

31.4 ± 3.75

0.9568

29.8 ± 4.87

0.3274

Hemoglobin (g/dL)

10.8 ± 0.81

11.5 ± 0.58

0.0192

10.7 ± 1.28

0.9602

10.1 ± 1.66

0.3318
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Figure 3-3 Mean serum electrolyte levels throughout the experimental procedure timepoint in
hyponatremic (n=10), isonatric (n=8), and hypernatremic (n=9) arms. Error bars represent standard
error of the mean. Statistical significance bars denote significant differences between groups at
individual timepoints.
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3.3.3 Levels of Syndecan-1
Two-way ANOVA analysis of syndecan-1 levels showed statistically significant effect of
timepoint (F (1.383, 33.19) = 88.30, p <0.0001, Figure 3-2), but no group effect (F (2, 24) = 0.9408,
p = 0.4042). Post-hoc testing revealed increases in percent change in syndecan-1 between sham
and 2 hr HD in the isonatric (42.6 ± 39.2% vs. 113.9 ± 64.5%, p = 0.0030), hyponatremic (27.8 ±
30.6% vs. 85.9 ± 48.2%, p = 0.0034), and hypernatremic (51.3 ± 56.6% vs. 178.2 ± 108.1%, p =
0.0024) groups. Elevation in percent change in syndecan-1 was also evident from 2 hr HD to the
final experimental timepoint as assessed by post-hoc testing in the isonatric (113.9 ± 64.5% vs.
228.3 ± 135.9%, p < 0.0155), hyponatremic (85.9 ± 48.2% vs. 237.7 ± 90.9%, p < 0.0001), and
hypernatremic (178.2 ± 108.1% vs. 265.6 ± 155.5%, p = 0.0270) groups. The percent change in
syndecan-1 at 2hr HD were assessed by post-hoc testing. The isonatric and hyponatremic group
showed comparable levels of syndecan-1 in the blood (113.9 ± 64.5% vs. 85.9 ± 48.2%, p =
0.5780). However, the percent change in syndecan-1 nearly doubled in the hypernatremic group
(178.2 ± 108.1%) compared to the hyponatremic group at 2hr HD (p = 0.0896).
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Figure 3-4 Mean plasma sodium levels (left y-axis) throughout the experimental procedure
timepoint in isonatric (A), hyponatremic (B), and hypernatremic (C) arms. Mean percent change
in syndecan-1 concentration (right y-axis) throughout the experimental procedure timepoint in
isonatric (A), hyponatremic (B), and hypernatremic (C) arms. Error bars represent standard error
of the mean. Dotted statistical significance bars denote significant differences in % change in
syndecan-1 between experimental timepoints.

3.3.4 Microvascular Perfusion
The absolute microvascular perfusion index measured as the number of identified points
using intravital microscopy was compared using a two-way ANOVA. The two-way ANOVA
demonstrated a significant effect of time (F (2.033, 46.76) = 19.38, p < 0.0001, Figure 3-3), but no
significant effect of group. Post-hoc testing showed a trend towards a decreased microvascular
perfusion index at 2hr HD compared to baseline in the isonatric group (116.7 ± 48.8 points vs.
154.1 ± 60.0 points, p = 0.0889). A trend towards a decreased microvascular perfusion index at
2hr HD compared to sham in the hyponatremic group (111.8 ± 55.7 points vs. 145.2 ± 42.2 points,
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p = 0.0982) was also observed. The hypernatremic group demonstrated a statistically significant
reduction in the microvascular perfusion index from baseline (208.9 ± 68.9 points) and sham
(166.5 ± 46.0 points) to 2 hr HD (119.9 ± 39.7 points) (p = 0.0098 and p < 0.0103, respectively).
A trend towards a decreased microvascular perfusion index at 1hr HD compared to baseline in the
hypernatremic group (146.5 ± 36.9 points vs. 208.9 ± 68.9 points, p = 0.0622) was also observed.
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Figure 3-5 Mean plasma sodium levels (left y-axis) throughout the experimental procedure
timepoint in isonatric (A), hyponatremic (B), and hypernatremic (C) arms. Mean number of
identified points (right y-axis) throughout the experimental procedure timepoint in isonatric (A),
hyponatremic (B), and hypernatremic (C) arms. Error bars represent standard error of the mean.
Dotted statistical significance bars denote significant differences in identified points between
experimental timepoints.
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3.3.5 Relationship between Microvascular Perfusion and Syndecan-1
A Pearson correlation analysis demonstrated a negative association between percent
change in syndecan-1 and the microvascular perfusion index measured by the number of identified
points (R2 = 0.13, Pearson r = -0.36, p = 0.0012). In other words, a greater change in syndecan-1
from baseline levels was associated with decreased number of identified perfusion points (Figure
3-4).
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Figure 3-6 Correlation in number of identified perfusion points and percent change in syndecan1 in all subjects (n=27).
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3.3.6 Mean Arterial Pressure
Linear mixed model analysis of mean arterial pressure for assessment of hemodynamic
stability showed a significant effect of experimental timepoint (F (2.642, 61.65) = 93.53, p <
0.0001). Post-hoc testing showed that, in the standard isonatric group, the mean arterial pressure
did not change from baseline to sham (88.6 ± 10.5 mmHg and 87.1 ± 9.9 mmHg, p = 0.9843).
However, in the hyponatremic and hypernatremic groups, there was a trend towards decreasing
mean arterial pressure from baseline to sham. At baseline, the mean arterial pressure was 85.3 ±
2.1 mmHg at baseline and reduced to 81.0 ± 4.5 mmHg in the hyponatremic group at sham (p =
0.0694) with one hour of extracorporeal circuit in the absence of dialysate flow. In the
hypernatremic group, the mean arterial pressure was 85.8 ± 8.2 mmHg at baseline and reduced to
75.5 ± 8.1 mmHg at sham (p = 0.0825). Compared to baseline, post-hoc testing showed that the
mean arterial blood pressure was significantly lower at 1 hr HD and 2 hr HD in all three
experimental groups as shown in Figure 3-5A. The mean arterial pressure did not recover to
baseline levels during the remainder of the experiment. Post-hoc testing revealed no significant
differences in mean arterial pressure between the experimental groups.

3.3.7 Relationship between Mean Arterial Pressure and Syndecan-1
A Pearson correlation analysis demonstrated a negative association between percent
change in syndecan-1 and mean arterial pressure (R2 = 0.07, Pearson r = -0.2645, p = 0.019). In
other words, a larger change in syndecan-1 from baseline levels was associated with lower levels
of mean arterial pressure (Figure 3-5B).
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Figure 3-7 (A) Experimental changes in mean arterial pressure in the isonatric (n=8),
1hr HD

2hr HD

hyponatremic (n=10), and hypernatremic (n=9) groups. Error bars represent standard error of the
mean. Statistical significance bars denote significant differences mean arterial pressure between
experimental timepoints. (B) Correlation in mean arterial pressure and percent change in
syndecan-1 in all subjects (n=27).

3.4 Discussion
The objective of this study was to study hemodialysis-induced endothelial injury with the
specific question of whether acute changes in plasma sodium during dialysis were a contributor.
First, the results of this study confirmed that HD directly led to endothelial damage. Plasma
syndecan-1 levels increased over the course of dialysis in all animals, regardless of whether they
were members of the hypernatremic, isonatric, or hyponatremic groups. This replicates prior
studies in human subjects demonstrating increasing levels of syndecan-1 that is associated with
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HD treatment

28,29

. Animals also demonstrated a marked reduction in mean arterial pressure

throughout dialysis, while mean arterial pressure remained consistent throughout the sham
procedure (removal of volume via an extracorporeal circuit without dialysis), confirming that HD
induces hypotension, and replicating the well-demonstrated phenomenon of intradialytic
hypotension and hemodynamic circulatory stress that occurs during HD 1,2,30–40 Interestingly, we
showed an association between the mean arterial pressure and the percent change in syndecan-1,
with low mean arterial pressure being associated with high levels of plasma syndecan-1. This
suggests that increased hemodynamic instability during dialysis is associated with increased
endothelial dysfunction. In other words, hypotension and circulatory stress can lead to endothelial
injury.
The results of our study also show that HD-induced endothelial injury is significant with
respect to microvascular dysfunction and microcirculatory perfusion. Using the microvascular
perfusion index derived from intradialytic intravital microscopy, statistical analysis showed a
significant effect of time, suggesting that, across the entire cohort of animals, perfusion decreased
over the course of dialysis. This is consistent with prior work done by our group, which showed a
significant reduction in microvascular perfusion from baseline to 2hr into HD in animals exposed
to standard dialysate with 140 mM of sodium24. In the present study, a pattern of microvascular
perfusion index decrease was seen in the isonatric group in the same timepoints in post-hoc
analysis adjusted for the additional multiple comparison tests required to compare the experimental
groups over time with changes in plasma sodium. However, when perfusion trends for the standard
sodium level group was assessed separately with an ordinary one-way ANOVA, the result was
replicated, with a statistically significant reduction of perfusion from baseline to 2hr HD. Together,
the simultaneous intradialytic increase in syndecan-1 and intradialytic decrease in microvascular
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perfusion index suggests that HD-induced endothelial injury is significant with respect to
perfusion. Indeed, a significant association between plasma syndecan-1 levels and microvascular
perfusion index was demonstrated, with higher levels of syndecan-1 associated with a lower
microvascular perfusion index.
Plasma sodium levels during dialysis appear to mediate the HD-induced endothelial injury
and microvascular hypoperfusion. In the hypernatremic group, cumulative syndecan-1 shedding
tended to be higher than in the isonatric and hyponatremic groups. Post-hoc analyses of
microvascular perfusion index demonstrated a significant reduction in microvascular perfusion
index with dialysis in the hypernatremic group but not in the isonatric and hyponatremic groups.
These results suggest that increased plasma sodium levels during dialysis secondary to a higher
sodium dialysate prescription aggravates endothelial injury and exacerbates microvascular
perfusion. This is consistent with human studies looking at acute sodium changes and endothelial
injury. In one study by Koch et al., where hemocontrol hemodialysis was employed, plasma
sodium levels were manipulated during dialysis and plasma syndecan-1 levels were measured;
plasma syndecan-1 levels tracked with plasma sodium levels increased with acute rise in plasma
sodium16. In general, these results lend support to the view that lower dialysate sodium
concentrations may be the way forward and that supra-physiological dialysate sodium
concentrations should be avoided. Not only can lower dialysate sodium concentrations lead to
more modest intradialytic weight gain and reduced tissue deposition of sodium41, it may also lower
the severity of HD-induced endothelial injury.
As this study’s primary objective was to study the effects of dialysate sodium in HDinduced injuries, it was important to ensure that sodium concentration delivered to the animals
matched the prescribed dialysate sodium and to show that sodium levels were successfully
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manipulated with the dialysate used. Indeed, the mean sodium dialysate levels were the same
within group, but significantly different between isonatric, hyponatremic, and hypernatremic
groups. This is often a point of concern in human studies, with a recent study conducted by Shendi
et al. showing discrepancies between the prescribed dialysate sodium and the sodium concentration
that was delivered to the patient through dialysis42.
This study had its limitations. This was an exploratory study, and its primary objective was
to investigate the effects of sodium dialysate on endothelial cell injury and microvascular
perfusion. For this purpose, healthy animals with normal kidney function were used to eliminate
confounding factors associated with kidney failure. To holistically understand the mechanism of
sodium induced injury in HD, future studies should be conducted on chronic kidney disease model
of animals. A major limitation of utilizing a small animal experimental platform is the availability
of blood. Based on the IACUC guideline, the total blood volume of a 300g rat is estimated to be
17 to 21mL. Increasing the number of times blood is sampled can lead to harmful hemodynamic
instability in a study that is already removing large volume of blood into the extracorporeal circuit.
Hence, we were limited with the amount of blood that could be sampled during this experiment.
Because of the nature of the preclinical platform in this current study, including the surgical
exposure of tissue for intravital microscopy, animals were sacrificed at the end of the HD treatment
preventing a cross-over design that has been used in human studies16 to enable a paired comparison
analysis that eliminates covariates in the relationship between plasma sodium and syndecan-1.

3.5 Conclusion
In this study, we demonstrate that during a single HD session, there are marked elevations
in levels of syndecan-1 that is associated with the reduction in microvascular perfusion. Through
the small animal model of healthy rats, we conclude that HD treatment itself induce endothelial
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injury and microcirculatory dysfunction. As well, the degree of damage to the glycocalyx may be
more pronounced with hypernatremic effects of high sodium dialysate leading to structural and
function changes to the microvasculature.
The optimal dialysate sodium concentration to deliver during HD is not known. Lower
dialysate sodium is ideal considering the deleterious effects of high sodium levels on the
endothelium, exacerbating HD-induced circulatory dysfunction and ischemia to the extent of
worsening myocardial stunning. However, sodium level must be sufficient enough to avoid
inducing intradialytic hypotension and hemodynamic injury. Clinically, dialysate sodium
concentration should be manipulated and individualized to each patient’s needs and further refined
through iterative evaluation of intradialytic weight gain, hemodynamic stability, sodium
deposition in the tissue and symptoms of intolerability.
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Chapter 4

4 A Pilot Study: Assessment of intradialytic exercise on the
circulation and function of the heart
A version of this chapter is in preparation for publication: Lisa Hur, Jarrin Penny, Justin Dorie,
Christopher W. McIntyre, “A Pilot Study: Assessment of intradialytic exercise on the circulation
and function of the heart ,” In preparation. Aug 2022.

Abstract Hemodialysis (HD) is associated with high rates of cardiovascular mortality.
Intradialytic exercise (IDE) has been shown to improve intradialytic hemodynamic tolerability,
although its mechanisms remain elusive. The objective of the present study was to use intradialytic
CT perfusion imaging and echocardiography to noninvasively evaluate cardiac injury during HD
with and without exercise. Fourteen participants underwent two intradialytic imaging sessions with
and without exercise. In both visits, dynamic CT scans (Revolution CT, GE) were conducted at
baseline, peak HD stress, and 30 mins post HD. From the CT scans, global myocardial perfusion
(MP) of the left ventricle was quantified. In addition, apical 4-chamber and 2-chamber views of
the heart were acquired with 2D echocardiography (Vivid Q, GE). The systolic function was
evaluated through segmental longitudinal strain (LS) using a commercially available software
(EchoPAC, GE). Segments demonstrating >20% reduction in LS compared to baseline were
defined as regional wall motion abnormalities (RWMA). During the control visit, MP significantly
dropped from baseline to peak HD stress (p=0.0001) followed by partial recovery post HD. Similar
intradialytic MP results were found with IDE. MP of control and exercise visits were not
significantly different. The number of myocardial segments experiencing RWMA at post HD were
reduced with IDE in comparison to the peak HD stress (p = 0.0009). A decrease in the number of
RWMAs post-HD with exercise suggests potential exercise-associated cardiac resilience to HDinduced cardiac ischemia injury.
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4.1 Introduction
Hemodialysis (HD) patients have elevated mortality rates related to cardiovascular disease
and specifically, sudden cardiac death1–3. Many imaging modalities have been utilized to study the
perfusion changes of vital organs during HD, including arterial spin labelled magnetic resonance
imaging4,5, computed tomography6,7, and positron emission tomography8,9. These studies
demonstrated HD-induced injury during a single treatment session. In addition, some studies also
investigated the phenomenon of recurrent and transient myocardial ischemia causing persistent
left ventricular dysfunction in the HD population, by looking for the presence of myocardial
stunning10–19. Echocardiography throughout HD and identifying reduced segmental regional wall
motion abnormalities (RWMAs) has been the preferred means to assess HD-induced myocardial
stunning20,21. In sum, the existing literature suggests that HD precipitates recurrent harm and is
responsible for the increased mortality in patients upon the first year of dialysis initiation22.
In the past decade, studies have investigated and employed various interventions to reduce
the hemodynamic perturbation during HD, detailing the practicability of incorporating it into
clinical practice; all of which rely on different mechanisms to target hemodynamic tolerability to
HD. One of the most safe and effective ways of minimizing intradialytic hypotension and exerting
protective effects on multiple vascular beds is through the delivery of cooled dialysate to increase
peripheral vasoconstriction23,24. This simple approach has been shown to reduce the presence and
severity of HD-induced ischemia25,26 and improve left ventricular circumferential fiber
shortening27. Cooling the dialysate has no addition cost associated with it and can be delivered on
any dialysis machine. Biofeedback dialysis technology is another way of reducing hypotension
and ischemia during dialysis, through active modulation of ultrafiltration rate and conductivity of
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the dialysate during the HD treatment session28. Despite its effectiveness, it is limited in
availability as it utilizes a specific dialysis machine restricting its application in clinical settings.
Intradialytic exercise (IDE) has been the intervention of interest in the recent years that
demonstrated clinical feasibility29–46. In summary, patients would perform an exercise regime
determined by the dialysis clinic while dialyzing on the dialysis chair. Many studies suggest that
exercise benefits the HD cohort by increasing quality of life, muscle power, and dialysis efficacy.
Systematic reviews have suggested an improvement in peak oxygenation uptake (measure of
cardiopulmonary capacity) by 23% with exercise43. In a clinical crossover design study, Kt/V was
calculated to evaluate dialysis efficacy, where K is the dialyzer clearance (mL/min), t is the
duration of dialysis treatment (mins), and V is the volume of distribution of urea clearance (mL)
47

. Exercise intensity and its effect on Kt/V was questioned; the study observed an increase in

dialyzer urea clearance with IDE relative to control but no significant difference between varying
exercise intensities. Similarly, an exploratory study was conducted by our lab and a reduction in
RWMAs was shown with exercise with no statistical significance between exercise doses48. These
results were confirmed by others, suggesting that IDE is cardioprotective against myocardial
stunning with respect to HD treatment40,49–51; its mechanism remains elusive. These studies have
proposed improved muscle perfusion and changes to vascular tone as potential underlying
mechanisms for exercise improving HD tolerability. However, no studies to date have investigated
the perfusion response to IDE.
Using multimodal intradialytic imaging, this study will, for the first time, investigate the
circulatory response to IDE and determine its ability to deliver cardioprotection to HD in exercisenaïve dialysis patients. To do so, echocardiography and cardiac computed tomography (CT)
perfusion imaging will be incorporated to quantify RWMAs and changes to myocardial blood flow
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throughout HD treatment. In addition, ELISA experiments will be performed to assess endothelial
injury in the vasculature with respect to HD treatment and IDE intervention by quantifying levels
of syndecan-1. We hypothesize that IDE is not driven by perfusion-related mechanisms, but rather
by means of cardioprotection to improve ischemic tolerability of the tissue in the HD setting of
challenged perfusion.

4.2 Methods
4.2.1 Study Design
This is a single-centered cross-sectional study designed to investigate the effects of
intradialytic exercise in a cohort of ESRD patients undergoing HD. Consented patients participated
in two study visits: a control visit with no intervention and a treatment visit with exercise during
HD. At each study visit, a series of dynamic contrast enhanced computed tomography (DCE-CT)
images and echocardiography images were acquired prior to HD (baseline), at the last thirty
minutes of HD during maximal circulatory stress (peak HD), and following the end of HD (post
HD) to quantify myocardial perfusion and stunning. Blood samples were collected at timepoints
corresponding to the image acquisition to assess intradialytic electrolyte changes and endothelial
dysfunction.

4.2.2 Study Population
This study was an extension of the work presented in Chapter 2 of this thesis. The
participants enrolled in the study presented in the previous chapter were asked to attend a second
imaging visit where intradialytic exercise was performed. The participants were recruited from the
London Health Science Centre Renal Program (London, Ontario, Canada). Fourteen exercisenaive participants, 18 years of age or older who had received HD for a minimum of three months,
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thrice weekly were enrolled. Those enrolled provided informed consent prior to the initiation of
the study. Patients with a prior diagnosis of chronic arrhythmia on anti-arrhythmic drugs or with a
pacemaker or cardioverter defibrillator were excluded.

4.2.3 Demographic Information
The demographic information collected from the participants included the death of birth
(month and year), age, biological sex, body mass index, ethnicity, and chronic kidney disease
related patient information.

4.2.4 Dialysis Treatment Information
The control and exercise study visits were conducted midweek and the dialysis treatments
delivered at both visits were consistent with what was described in Chapter 2.

4.2.5 Assessment of Hemodynamic Stability
Hemodynamic stability of the participants throughout the HD treatment at the control and
exercise exposure visit was assessed by measuring the systolic blood pressure (mmHg).
Measurements were acquired while the patient was sitting on a dialysis chair and was obtained
within five minutes of CT imaging at baseline, peak HD stress, and post HD treatment.

4.2.6 Exercise Performance
On the second study visit, participants began exercise treatment at the start of the HD
treatment for a duration of thirty minutes. At this time, participants cycled on a MonarkTM
(Sweden) leg ergometer to reach an exercise intensity threshold of 3 or 4 out of 10 on a Borg rating
of perceived exertion scale, defined as moderate or somewhat hard. Participants cycled whilst
upright and sitting on a dialysis chair. Participants were encouraged to take rest periods throughout
the thirty minutes of exercise if they were experienced any symptoms of exercise intolerance such
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as shortness of breath and angina. Following the end of the exercise treatment, the following data
were recorded from the cycling device: calories burnt during exercise, number of rotations, and
the minutes spent exercising without rest within the 30-minute exercise prescription. From these
measurements, the number of rotations per minute and the amount of calories burnt per minute
were quantified.

4.2.7 Quantification of Myocardial Perfusion
During each study visit, a DCE-CT image was acquired at baseline, peak HD stress, and
post HD. Iodinated contrast agent of 0.7mL per kilogram of body weight (Isovue 370) was
administered intravenously at 3-4mL/s followed by a 30mL bolus saline flush at the same infusion
rate. Scanning was conducted using a single-phase prospective ECG gated acquisition protocol:
32 axial scans every 1 to 2 heart beats (approximate 1.5 seconds). The scanner settings for all
dynamic image acquisitions were as follows: tube voltage of 100 to 120kV, tube current of 100mA,
0.28s gantry period, slice thickness of 2.5mm giving a total coverage of 160mm.
The dynamic CT images were retrospectively reconstructed into 5mm thick cardiac images
from the scanner console (Revolution, GE Healthcare) and transferred to a workstation for analysis
(Advantage workstation, GE Healthcare). To correct for the residual cardiac and respiratory
motion between the 32 scans of a single dynamic CT image set, the images were registered using
a three-dimensional non-rigid registration algorithm (GE proprietary software, advantage
workstation, GE Healthcare).
Following motion correction, the Johnson-Wilson-Lee tracer kinetic model was
implemented to the registered dynamic images to generate a myocardial perfusion map
corresponding to each slice53–57. The left ventricular myocardium was delineated for seven slices
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with visible apex, apical, mid, and basal regions of the heart to measure global myocardial
perfusion. The global myocardial perfusion values of the seven slices were averaged to represent
the mean global myocardial perfusion of the patient at a particular timepoint of a single study visit.

4.2.8 Assessment of Regional Wall Motion Abnormality
Echocardiography was conducted to acquire standard apical 4-chamber and 2-chamber
views of the heart following the DCE-CT acquisition at baseline, peak HD stress and post HD
timepoints during the control and exercise study visits. Three cardiac cycles were recorded at each
cardiac view for offline digital analysis using a proprietary two-dimensional speckle tracking
software (EchoPac, GE Healthcare). The longitudinal strain values for twelve myocardial
segments were quantified using a single cardiac cycle at a given HD timepoint.
The longitudinal strain values of the twelve myocardial segments at peak HD and post HD
were normalized to its baseline values to calculate the percent change in longitudinal strain. The
myocardial segments at peak HD and post HD with greater than twenty percent reduction in
longitudinal strain in relation to the baseline values were identified to be segments with RWMAs.
The total number of segments (out of 12) experiencing RWMAs were determined at peak HD and
post HD for study visits and was used as a metric to study the effect of intradialytic exercise on
myocardial stunning.

4.2.9 Quantification of Endothelial Dysfunction
Blood samples collected at control and exercise visits for baseline, peak HD stress, and
post HD timepoints. The plasma from all participants were stored at -80°C freezer until processed
using a commercially available ELISA kit to quantify human syndecan-1 (Abcam, ab46506). All
ELISAs were performed according to the manufacturers’ instruction manual. Reference standards
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were within the limits of detection and were fitted with a 4-parameter logistic model. This model
was used to estimate the concentration of syndecan-1 in blood samples. The percent change in
syndecan-1 concentration at peak HD and post HD relative to baseline was calculated for each
visit to study the acute effects of intradialytic exercise on syndecan-1, a marker of endothelial
dysfunction and injury.

4.2.10

Statistical Analysis

All statistical tests of global myocardial perfusion, RWMAs, and syndecan-1 were
completed using IBM SPSS Statistics version 27 (IBM, Armonk, New York, United States of
America). Statistical test of patient demographics, dialysis prescription, intradialytic treatments,
and changes in laboratory blood measurements were performed using GraphPad Prism 9
(GraphPad Software, La Jolla, California, United States of America). Figures presented in this
manuscript were produced using GraphPad Prism 9 (GraphPad Software, La Jolla, California,
United States of America).

4.2.10.1 Participant Demographics and Dialysis Treatment Information
Demographic information and prescribed dialysis treatment information for the fourteen
participants are summarized with descriptive statistics (minimum value, maximum value, mean
and standard deviation) in Table 4-1 and Table 4-2.

4.2.10.2 Intradialytic Clinical Information at the Study Visits
Intradialytic clinical parameters including pre-systolic blood pressure (SBP), pre-diastolic
blood pressure (DBP), SBP nadir, DBP nadir, Kt/V, minimum relative blood volume (RBV), mean
ultrafiltration rate (UFR), mean UFR relative to pre-HD weight, and total volume of fluid removed
during HD were compared between visits. A parametric paired two-tailed t-test was performed for
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each of the listed parameters to determine differences in the delivered treatment between visits
(control vs. exercise).

4.2.10.3 Assessment of Hemodynamic Stability
Hemodynamic stability was assessed using SBP measurements acquired at baseline, peak
HD, and post HD. A repeated measure two-way ANOVA with visit (control or exercise), timepoint
(baseline, peak HD, post HD), and visit-by-timepoint as fixed effects was perform for the SBP
measurements. A Geisser-Greenhouse correction was applied. If any of the fixed effects were
statistically significant, post-hoc tests were performed with Tukey’s correction for multiple
comparison to determine SBP differences between intradialytic timepoints and between groups.

4.2.10.4 Exercise Treatment Information
The intradialytic exercise information for the twelve participants is summarized with
descriptive statistics (minimum value, maximum value, mean and standard deviation) in Table 44.

4.2.10.5 Laboratory Testing
Intradialytic changes in electrolyte and protein concentrations measured from the blood
samples were assessed using linear mixed models. Levels of ionized calcium, sodium, potassium,
chloride, bicarbonate, anion gap, creatinine, urea, albumin, calcium, magnesium, phosphate,
parathyroid hormone (PTH), cardiac troponin T (cTnT), hemoglobin, hematocrit, and C-reactive
protein (CRP) were analyzed using linear mixed models with intradialytic timepoint and visit
(control and exercise) as the fixed effect. A maximum likelihood algorithm was used to estimate
variance parameters. The Geisser-Greenhouse correction was applied to correct for the sphericity
of the data. If any fixed effect was statistically significant, post-hoc testing was completed with
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Sidak’s correction for multiple comparison to identify difference in electrolyte between timepoints
and between visits.

4.2.10.6 Percent Change in Syndecan-1 Concentration
The percent change in syndecan-1 concentration was measured at peak HD and post HD
relative to the baseline syndecan-1 concentration. A repeated measure two-way ANOVA test with
intradialytic timepoint and visit (control or exercise) as fixed effects were performed with GeisserGreenhouse correction for sphericity. If any fixed effect was statistically significant, post-hoc
testing was completed with Sidak’s correction for multiple comparison to determine differences
in syndecan-1 between visit and between intradialytic timepoints.

4.2.10.7 Global Myocardial Perfusion
A grouped (control vs. exercise) analysis was performed to investigate the effect of exercise
on global myocardial perfusion during dialysis. A linear mixed model with visit (control or
exercise) and intradialytic timepoint as fixed effects was performed with restricted maximum
likelihood estimation and the Geisser-Greenhouse correction. Post-hoc testing with Sidak’s
correction for multiple comparison was performed to identify differences in myocardial perfusion
between visits and between timepoints

4.2.10.8 Regional Wall Motion Abnormality
The number of myocardial segments experiencing RWMAs was analyzed using a linear
mixed model with visit (control vs. exercise), intradialytic timepoints, and interaction between
visit and timepoints as fixed effects. A Geisser-Greenhouse correction was applied for this analysis
for sphericity. If any of the fixed effects were significant, post-hoc tests were completed with
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Sidak’s correction for multiple comparison to identify differences in the number of myocardial
segments experiencing RWMAs between visit and between timepoints.

4.3 Results
4.3.1 Participants
Of the fourteen, twelve participants completed both the control and exercise study visits.
One participant did not complete the exercise treatment visit due to death. Another participant was
unable to complete the exercise treatment visit due to HD-related complications. As a result,
twelve participants had a total of six DCE-CT images (control visit = 3 images; exercise visit = 3
images). Of the twelve participants, a single perfusion map of a participant at post HD during the
exercise visit could not be generated due to a defect in the software.
Echocardiography data were obtained in fourteen participants (control visit=14
participants; exercise visit = 12 participants). Due to poor image quality, RWMA measurements
could not be retrieved for the control visit of one patient. Additionally, for the same reason,
RWMA measurement could not be retrieved for the exercise visit of one patient. In total, thirteen
RWMA measurements were available for analysis in the control visit for each timepoint and eleven
RWMA measurements were available in the exercise visit for each timepoint.
All fourteen participants completed the blood work for the visits attended. However, of the
fourteen participants, plasma samples of only eleven participants were analyzed for change in
syndecan-1 concentration due to limitations in resources.
The participants demographic information for this study is summarized in Table 4-1. A
summary of the participants regular dialysis prescription is given in Table 4-2.
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Table 4-1 Participant information and demographics
Characteristics
Ethnicity: Caucasian, n
Men, n
Age, yr
BMI
Dialysis vintage (mo)
Hemodialysis vintage (mo)
Charlson comorbidity index*
Congestive heart failure
Primary renal diagnosis
Hypertension
Hypertensive nephrosclerosis
Diabetic nephropathy
Acute Interstitial Nephritis
IgA nephropathy
Current Smoker
Medications
ACEi/ARB
b - blocker
2+ antihypertensive agent

Prevalence
10 (71%)
9 (64%)
66 ± 13
33 (26-41)
60 (20-141)
53 (16-141)
7 (4-12)
4 (29%)
4 (29%)
3 (21%)
6 (43%)
1 (7%)
2 (14%)
1 (7%)
5 (36%)
7 (50%)
5 (36%)

*Age-adjusted

Table 4-2 Mean dialysis prescription (n=14)
Dialysis Prescription
Treatment Time (hr ± SD)
Sodium (mmol/L ± SD)
Calcium (mmol/L ± SD)
Bicarbonate (mmol/L ± SD)
Dialysis flow, Qd (ml/min ± SD)
Vascular Access (AVF: AVG: CVC)*

3.5 ± 0.7
139 ± 1.8
1.3 ± 0.1
37.4 ± 2.3
543 ± 109
6:1:7

*AVF = arteriovenous fistula; AVG = arteriovenous graft;
CVC = central venous catheter
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4.3.2 Dialysis Treatment
The dialysis treatment is summarized in Table 4-3 and includes weight +gain/-loss, presystolic blood pressure (SBP), pre-diastolic blood pressure (DBP), SBP nadir, DBP nadir, Kt/V,
minimum relative blood volume (RBV), mean ultrafiltration rate (UFR), mean UFR relative to
pre-HD weight, and total fluid removed during the HD treatment session. The multiple paired
parametric t-tests revealed no differences in the listed parameters between visits and this is
summarized in more detail in Table 4-3.
Table 4-3 Intradialytic clinical information
Parameters

Control (n=14)

Weight +gain/-loss (kg ± SD)
1.4 ± 0.7
Pre HD SBP (mmHg ± SD)
149 ± 20
Pre HD DBP (mmHg ± SD)
64 ± 18
SBP nadir (mmHg ± SD)
106 ± 21
DBP nadir (mmHg ± SD)
55 ± 16
Kt/V ± SD
1.47 ± 0.3
Min RBV (% ± SD)
85.0 ± 3.3
Mean UFR (mL/hr ± SD)
662 ± 196
Mean UFR/pre weight (mL/kg/hr ± 7.50 ± 2.6
SD)
Total fluid removed (mL± SD)
2539 ± 785

Exercise (n=12)

p-value

1.8 ± 0.7
143 ± 22
64 ± 14
101 ± 16
56 ± 14
1.46 ± 0.3
84.7 ± 4.6
733 ± 190
8.5 ± 2.9

0.8162
0.4772
0.8301
0.6499
0.4921
0.6079
0.8440
0.6065
0.5277

2847 ± 732

0.4829

*SBP = systolic blood pressure; DBP = diastolic blood pressure; RBV = relative blood volume; UFR = ultrafiltration
rate

4.3.3 Systolic Blood Pressure for Hemodynamic Stability
The repeated measure two-way ANOVA demonstrated a significant effect of timepoint (F
(1.824, 43.77) = 22.17, p < 0.0001). The post-hoc testing showed that SBP was significantly lower
at peak HD in comparison to baseline in the control (120.9± 23.8 mmHg vs. 145.0 ± 23.9 mmHg,
p = 0.0179) and exercise visit (112.2 ± 15.2 mmHg vs. 142.4 ± 19.5 mmHg, p < 0.0001, Figure 41). SBP post HD was not significantly different from baseline during the control visit (126.0 ±
25.8 mmHg, p = 0.0615) but was significantly reduced during the exercise visit (123.3 ± 22.4
142

mmHg, p = 0.0038). The repeated measure two-way ANOVA did not show significant effect of
visit (control vs. exercise) on SBP (F (1, 24) = 0.4139, p = 0.5261).
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Figure 4-1. Mean systolic blood pressure measured at baseline (pre HD initiation), peak HD stress
and post HD at the control and exercise treatment visit. Error bars represent standard error of the
mean. * Denote p < 0.0332, ** denote p < 0.0021, **** denote p < 0.0001.

4.3.4 Exercise Prescription Information
The exercise treatment is summarized in Table 4-4 and includes calories burnt during
exercise, the number of rotations (count), the number of rotations per minute (RPM), and the
amount of calories burnt per minute (CPM).

Table 4-4 Mean exercise information (n=12)
Patient exercise information

Mean ± SD (Min – Max)
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Calories (cal ± SD)
Count (# of rotations ± SD)
RPM (# of rotation/min ± SD)*
CPM (cal/min ± SD)*

108.4 ± 162.3 (9.4 – 479.0)
1235 ± 933 (14.3 – 3340)
50.67 ± 31.96 (0.77 – 133.6)
3.86 ± 6.91 (0.98 – 25.7)

*RPM = rotations per minute; *CPM = calories per minute

4.3.5 Laboratory Testing
The electrolyte and protein concentrations measured at baseline, peak HD, and post HD
included ionized calcium, sodium, potassium, chloride, bicarbonate, anion gap, creatinine, urea,
albumin, calcium, magnesium, phosphate, PTH, cTnT, hemoglobin, hematocrit, and CRP. Linear
mixed modelling showed no significance in fixed effect of timepoint in levels of ionized calcium
(F (1.054, 24.77) = 3.690, p = 0.0644), calcium (F (1.220, 28.07) = 0.4901, p = 0.5262), and sodium
(F (1.298, 30.51) = 0.0123, p = 0.9522). The same electrolytes also showed no significant effect
of visits (control vs. exercise) in levels of ionized calcium (F (1, 24) = 0.0188, p = 0.8920), calcium
(F (1, 24) = 0.8099, p = 0.3771), and sodium (F (1, 24) = 0.0362, p = 0.8508).
Biomarkers of cardiac injury and inflammation analyzed were cTnT and CRP. Linear
mixed modelling indicated insignificant effect of timepoints and visits (control vs. exercise) in
levels of cTnT (timepoint: F (1.039, 24.93) = 3.755, p = 0.0627 and visit: F (1, 24) = 0.1110, p =
0.7419) and CRP (timepoint: F (1.003, 23.57) = 0.0257, p = 0.8746 and visit: F (1, 24) = 0.0016,
p = 0.9680).
Linear mixed modelling indicated significant effects of timepoint in the following
electrolytes and proteins: potassium, chloride, and bicarbonate, anion gap, creatinine, urea,
albumin, magnesium, phosphate, PTH, hemoglobin, and hematocrit. Post-hoc testing for multiple
comparison revealed expected intradialytic changes in these electrolytes and proteins. There was
no significant effect of visit (control vs. exercise) in the listed electrolytes. Details of these analyses
are summarized in Table 4-5 and shown in the Supplementary Figure 4-1.
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Table 4-5 Mean plasma electrolyte concentration of those with significant changes as a response
to hemodialysis treatment
Electrolyte (Conc. ± SD)
Potassium (mmol/L)
Chloride (mmol/L)
Bicarbonate (mmol/L)
Anion Gap (mmol/L)
Creatinine (umol/L)
Urea (mmol/L)
Albumin (g/L)
Magnesium (mmol/L)
Phosphate (mmol/L)
PTH (pmol/L)*
Hemoglobin (g/L)
Hematocrit (L/L)

Control (n=14)
Baseline
Peak HD
4.60 ± 0.8
3.32 ± 0.4
93.3 ± 3.2
91.9 ± 2.9
24.4 ± 2.5
29.8 ± 2.4
16.3 ± 3.8
12.7 ± 2.4
758 ± 207
274 ± 97
18.2 ± 4.6
5.19 ± 1.6
36.7 ± 3.9
41.8 ± 4.6
1.07 ± 0.2
0.96 ± 0.2
1.78 ± 0.5
0.72 ± 0.1
34.5 ± 21
42.6 ± 24
102 ± 10
112 ± 11
0.32 ± 0.03 0.35 ± 0.04

Post HD
3.34 ± 0.4
91.7 ± 3.0
29.9 ± 2.2
12.3 ± 2.6
268 ± 107
5.01 ± 1.8
40.7 ± 4.9
0.93 ± 0.2
0.78 ± 0.2
41.4 ± 24
109 ± 12
0.34 ± 0.04

Exercise (n=12)
Baseline
Peak HD
4.43 ± 0.7
3.24 ± 0.5
92.8 ± 3.2
91.6 ± 2.9
25.2 ± 2.4
29.8 ± 2.6
16.3 ± 3.7
12.8 ± 2.7
766 ± 210
275 ± 97
18.3 ± 5.9
5.1 ± 1.4
37.8 ± 2.5
41.7 ± 4.1
1.10 ± 0.3
0.91 ± 0.2
1.78 ± 0.7
0.77 ± 0.5
34.1 ± 17
43.9 ± 24
98.8 ± 9.9
109 ± 11
0.31 ± 0.03 0.33 ± 0.03

Post HD
3.22 ± 0.4
91.6 ± 2.5
29.8 ± 2.3
12.8 ± 2.8
274 ± 100
4.85 ± 1.4
42.0 ± 3.9
0.92 ± 0.2
0.80 ± 0.4
40.6 ± 21
106 ± 9.1
0.33 ± 0.03

*PTH = Parathyroid hormone

4.3.6 Percent Change in Syndecan-1
In the twelve participants with viable syndecan-1 measurements, a two-way ANOVA
revealed a significant effect of visit (control vs. exercise) on the percent change in syndecan-1 as
measured in the blood (F (1, 19) = 7.673, p = 0.0122). Post-hoc testing showed that at post HD,
the percent change in syndecan-1 relative to baseline was significantly higher in the exercise visit
(6.5 ± 5.9 %) than in the control (-4.1 ± 4.8 %, p = 0.0005, Figure 4-2). In the control visit, percent
syndecan-1 was reduced at post HD (-4.1 ± 4.8 %) from peak HD (0.9 ± 5.8%, p = 0.0270).
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Figure 4-2 Percent change in syndecan-1 concentration at peak HD stress and post HD treatment
relative to baseline syndecan-1 concentration. Error bars represent the standard error of the mean.
The significance bar represents statistical significance between visits. *** Denote p < 0.0002.

4.3.7 Global Myocardial Perfusion
The linear mixed model revealed a statistically significant fixed effect of timepoint (F (2,
13.21) = 23.26, p < 0.0001) and no effect of visit (F (1,13.47) = 3.216, p =0.095). The mean global
myocardial perfusion in the control visit decreases from 100.0 ± 9.4 ml/min/100g to 77.8± 5.5
ml/min/100g from baseline to peak HD (p = 0.002, Figure 4-3), and partially recovers to 88.7± 4.9
ml/min/100g post HD (comparison with baseline perfusion, p = 0.5330). Comparably, the mean
global myocardial perfusion during the exercise visit is reduced from 92.5 ± 7.4 ml/min/100g to
73.5± 3.5 ml/min/100g from baseline to peak HD (p = 0.015, Figure 4-3), and partially recovers
to 82.2± 5.1 ml/min/100g post HD (baseline vs. post HD: p = 0.2050 and peak HD vs. post HD: p
= 0.0090, Figure 3). Additional post-hoc testing demonstrated a trend towards increased
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myocardial perfusion in the control visit relative to the perfusion measurements obtained in the
exercise at post HD timepoint (88.7± 4.9 ml/min/100g vs. 82.2± 5.1 ml/min/100g, p = 0.072,
Figure 4-3).
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Figure 4-3. Mean global myocardial perfusion at baseline, peak HD stress, post HD during control
and exercise visit. Solid significance line represents statistical significance for the control visit.
Dotted significance line represents statistical significance for the exercise visit timepoint. Error
bars represent standard error of the mean. Grey significance line represents the statistical
significance between the control and exercise visits. * Denote p < 0.0332, ** denote p < 0.0021,
*** denote p < 0.0002.

4.3.8 Regional Wall Motion Abnormality
Linear mixed modelling revealed a statistically significant fixed effect of timepoint (F (1,
10.392) = 11.489, p = 0.007) and interaction between timepoint and visit (F (1, 9.847) = 6.789, p
= 0.027). Post-hoc testing showed no difference in the mean number of myocardial segments
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experiencing RWMAs at peak HD (5.4 ± 0.8 segments) and post HD (4.7± 0.7 segments, p =
0.289) at the control visit (Figure 4-4, ns, p = 0.29). With exercise, there was a reduction in
RWMAs from 5.6 ± 0.9 segments at peak HD to 3.2 ± 0.7 segments at post HD (Figure 4-4, p <
0.001). At post HD timepoint, there was a trend towards decreased number of RWMA with
exercise compared to the control (Figure 4-5B, p = 0.086).

RWMA (# of segments)

12
10
✱✱✱

8
6
4
2
0
Peak HD

Post HD

Figure 4-4. Mean number of myocardial segments experiencing regional wall motion
abnormality (RWMA) relative to baseline at peak HD stress and post HD during the control and
exercise visit. Dotted significance line represents statistical significance for the exercise visit.
Error bars represent the standard error of the mean. *** Denote p < 0.0002

148

(B)

12
10
8

12

Post HD RWMA (# of segments)

Peak HD RWMA (# of segments)

(A)

ns

6
4
2
0

10
8

p=0.08

6
4
2
0

Control

Exercise

Control

Exercise

Figure 4-5. (A) Mean number of myocardial segments experiencing regional wall motion abnormality
relative to baseline at peak HD stress during the control and exercise visit (B) Mean number of myocardial
segments experiencing regional wall motion abnormality relative to baseline at post HD timepoint during
the control and exercise visit. Error bars represent the standard error of the mean.

4.4 Discussion
This study is the first to investigate the effects of intradialytic exercise (IDE) on myocardial
perfusion and contractility during HD and its role in protection against HD-induced cardiac injury.
HD-induced cardiac injury is known to be in the form of myocardial hypoperfusion57. In the
present study, this was demonstrated by the control visit data (HD without IDE) which showed
that global myocardial perfusion was reduced at the peak HD timepoint, with partial perfusion
recovery following the end of HD. Similar results have been reported in previous studies57–59.
Intradialytic hypoperfusion and ischemia has been attributed to the significant hemodynamic
effects of HD treatment, especially intradialytic hypotension60–62. Indeed, we observed a reduction
in systolic blood pressure at peak HD, coinciding with when global myocardial perfusion
decreased.
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Reduced myocardial perfusion during HD leads to ischemic cardiac injury. A common
clinical marker of ischemic cardiac injury is the troponin level, and some studies have
demonstrated a relationship between HD and cardiac troponin T (cTnT) levels13,63–65. However,
no intradialytic change in plasma cTnT levels were observed in the present study. This may be
because elevation in cTnT after cardiac ischemia is a delayed response, with elevation typically
seen 6-12 hours following an ischemic event66.
Intradialytic exercise has long been hypothesized to increase myocardial perfusion and
decrease myocardial stunning, thereby attenuating intradialytic cardiac ischemic injury 67. Based
on the results of this study, this hypothesis does not appear to be entirely correct. We observed no
difference in the intradialytic changes in the myocardial perfusion between the control visit (HD
without IDE) and the exercise visit (HD with IDE). At both visits, global myocardial perfusion
decreased at peak HD with partial recovery following the end of HD, indicating that IDE does not
attenuate the perfusion defects caused by HD. IDE also did not affect the patient’s hemodynamic
response to HD, with no differences in intradialytic changes in SBP between both visits. At both
visits, SBP reduced at peak HD, followed by partial recovery post HD. This demonstrates that IDE
does not increase myocardial perfusion as hypothesized in the literature.
However, this is not to say that IDE does not impart cardioprotection. Using
echocardiography, this study demonstrated that the number of myocardial segments experiencing
regional wall motion abnormality was not significantly different between peak HD and post HD
during the control visit, while there was a statistically significant reduction in the number of
segments with regional wall motion abnormality from peak HD to post HD during the exercise
visit. This suggests that the contractile function of the heart may be protected with intradialytic
exercise. These results are consistent with other studies of Intradialytic exercise that also used
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echocardiography as a means to assess cardiac function. Previously, our group assessed cardiac
function using intradialytic echocardiography in 19 participants exposed to different amounts of
intradialytic exercise. Although global longitudinal strain (a measure of global myocardial
contractile function) did not improve with exercise, there were reductions in the number of
myocardial segments with RWMAs at peak HD stress with exercise exposure 48. Another study
conducted by McGuire et al., showed in 20 participants a reduced mean number of stunned
segments (i.e. segments with RWMAs) at 2.5 hours into HD, following exercise exposure one hour
into HD treatment51 .
Taken together, these results suggest that IDE does not impart cardioprotection by affecting
myocardial perfusion like other interventions such as dialysate cooling does, but by maintaining
cardiac contractility. Said another way, IDE appears to improve ischemic tolerability of cardiac
tissue in the setting of the same degree of HD-induced perfusion challenge. The mechanism by
which it does this remains unclear and is an area of further study.
The optimal prescription of IDE in terms of intensity, duration, and timing during the
dialysis session remains an open question. In our study, we administered IDE for 30 minutes upon
HD initiation. Other studies, such as the one done by McGuire et al., administered exercise one
hour into HD treatment for 30 minutes, closer to the time during HD at which a patient experiences
the most hemodynamic instability or HD-induced stress. Our study showed no difference in the
number of segments experiencing RWMA at peak HD (1 hour from the end of dialysis), whereas
McGuire et. al did demonstrate a difference at 2.5 hours into dialysis51. This discrepancy suggests
that the time window at which participants are exposed to exercise in relation to their HD treatment
may be crucial in minimizing myocardial abnormalities and optimizing cardioprotection.
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The intensity and duration of IDE may be less crucial for achieving optimal
cardioprotection, as previous work has shown that the dose of IDE had no affect on the number of
myocardial segments with RWMAs during dialysis48. However, it remains possible the
cardioprotection imparted by IDE is balanced against possible harms. One of these possible harms
is endothelial injury. The metric by which endothelial injury was assessed in the present study
was via measurement of plasma levels of sydecan-1, a dominant heparan sulfate proteoglycan,
propagating at the surface lining of the endothelial glycocalyx68, known to degenerate or shed into
the circulating blood in inflammatory conditions, during states of oxidative stress, and even due to
HD69–71. It has also been previously shown to increase in response to exercise72. Interestingly, in
our study a significant rise in plasma sydecan-1 from peak HD to post HD was demonstrated only
at the exercise visit, and not at the control visit. Thus, our IDE intervention appeared to have
induced shedding of the glycocalyx, which may be an indication of IDE-related endothelial injury.
Further study on the impact of IDE on the endothelium should be done to enable titration of IDE
dose to prevent IDE related endothelial injury.
The optimal prescription of IDE may also vary amongst patients with different
comorbidities such as those with a history of coronary artery disease or a history of myocardial
infarction. Further study to determine how IDE modulates cardiac perfusion and contractility in
patients with varying degrees of coronary artery stenosis would be valuable.
A number of limitations should be addressed. This study was a pilot study to demonstrate
the effect of intradialytic exercise on myocardial perfusion and regional wall motion abnormality.
As a result, it was completed on a small, predominately male cohort. However, a retrospective
effect size was calculated for myocardial perfusion and RWMAs between intradialytic timepoints
in the control and exercise visit. Cohen’s d value for our primary outcome measure of myocardial
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perfusion measurements were 0.77 between baseline and peak HD and 0.56 between peak HD and
post HD in the control visit. Cohen’s d value for myocardial perfusion measurements were 0.89
between baseline and peak HD and 0.43 between peak HD and post HD in the exercise visit. The
determined values suggested that the size of effect was medium to large. We also experienced
difficulty in painting the exact same exercise regime between patients, as patients differed in their
exercise tolerance levels secondary to limitations associated with CKD such as muscle atrophy
and existing cardiovascular disease.

4.5 Conclusion
To our knowledge, this is the first intradialytic study investigating the effects of
intradialytic exercise on cardiac perfusion and function using CT perfusion and echocardiography.
First, this study established that in an exercise-naive group of HD participants, a single small dose
of exercise was sufficient to induce endothelial damage during HD. Secondly, it was demonstrated
that intradialytic exercise did not affect the hemodynamic and electrolyte changes traditionally
seen with HD treatment. This study confirmed that the ischemia-reperfusion injury of the heart
resulted from the HD treatment itself that is recurrent at each HD treatment session. Most
importantly, the results of study indicated that intradialytic exercise did not affect the perfusion
response to HD but was able to mitigate cardiac dysfunction with the reduction in RWMAs.
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Chapter 5

5 Thesis Summary and Future Works
5.1 Project Summary and Conclusion
The purpose of this thesis was to study the microcirculatory changes during hemodialysis
(HD) in conditions of coronary artery stenoses, intradialytic exercise intervention, and alteration
of sodium dialysate. The scientific investigations that were conducted are summarized in this
section.

5.1.1 Presence of coronary artery stenoses reduces segmental myocardial
perfusion and is associated with myocardial stunning
Chapter 2 described an exploratory study where multimodal intradialytic imaging was used
to evaluate myocardial perfusion in fourteen individuals on hemodialysis treatment. Unlike studies
reported in the literature to date, this study did not exclude patients with coronary artery disease.
Interestingly, this study showed that systemic hemodynamics (as assessed using intradialytic blood
pressure measurements) and the global myocardial perfusion response (as assessed using
computed tomography perfusion imaging) did not change with the presence of coronary artery
stenoses. Ischemic myocardial injury associated with HD is apparent three hours from the initiation
of dialysis whether there is coronary artery stenosis or not.
It appears that coronary artery stenosis affects perfusion not at the global level, but at the
segmental level. Myocardial segments supplied by the stenosed coronary arteries experienced a
significant reduction in perfusion that did not recover to baseline levels following the end of HD
treatment. In contrast, the segments supplied by non-stenosed coronary arteries experienced a
recovery of perfusion to baseline levels at the end of HD treatment. Accordingly, the group of
participants with no coronary artery stenosis had fewer segments experiencing hypoperfusion
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(defined as a >30% reduction in myocardial perfusion relative to baseline) after HD compared to
during HD, while the group of participants with coronary artery stenosis had the same number of
segments experiencing hypoperfusion after HD as during HD. In other words, there was an absence
of perfusion recovery at the segmental level in the group of participants with coronary artery
stenosis.
The fact that coronary artery stenosis affects perfusion at the segmental level has
consequences that may be of clinical significance. The absence of perfusion recovery after HD in
the stenosed participant group was associated with the persistence of regional wall motion
abnormality after HD indicating myocardial stunning. Consistent with this, the stenosed participant
group also had higher levels of cardiac troponin T during HD, which remained elevated following
the end of HD treatment, while the non-stenosed participant group had troponin levels that
recovered following the end of HD.
Together this suggests that the presence of coronary artery stenosis may result in greater
and clinically significant amount of myocardial injury due to differences in segmental perfusion,
despite no detectable differences in systemic hemodynamics or global myocardial perfusion.

5.1.2 The effect of dialysate sodium
microcirculatory dysfunction

on

endothelial

injury

and

Dialysis does not only result in injury to vascular beds such as the heart at a global,
segmental, or macrovascular level, but also at a microvascular level. It has been well established
that ischemic injury can cause endothelial damage, but this may be exacerbated by significant
osmotic shifts during dialysis. Generally, dialysate fluid used during HD contains high sodium
concentrations to improve hemodynamic stability during HD, at the cost of significant sodium
loading. HD-induced sodium loading and the subsequent osmotic shift that takes place during HD
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can compound the endothelial damage caused by HD-induced ischemia. This is because it is the
endothelium that serves as a buffer for sudden serum sodium shifts. Endothelial cells have a
pericellular coat (glycocalyx) that contains transmembrane heparan sulfate proteoglycans such as
syndecan-1 which bind sodium.
The role of sodium loading due to dialysis in HD-associated microvascular injury is not
well understood. Chapter 3 described a study that aimed to study the effects of sodium loading
during HD on the endothelium. HD was performed on rodents without kidney disease using
dialysate that differed with respect to sodium composition. The resulting effects on the
microvasculature were assessed using intravital microscopy and plasma syndecan-1 levels.
Plasma syndecan-1 levels increased during dialysis at all three levels of dialysate sodium
tested (130, 140, and 150 mM). However, with higher dialysate sodium concentration (150 mM),
the level of syndecan-1 in plasma at two hours into dialysis was greater than baseline measures by
almost two-folds, whereas with lower dialysate sodium concentration (130, 140 mM) sydecan-1
levels only demonstrated a one-fold increase at two hours into dialysis relative to baseline. At the
intradialytic timepoints where syndecan-1 levels increased, there was a concomitant reduction in
microvascular perfusion only in the rats exposed to high sodium dialysate. Thus, this suggests that
sodium loading not only directly mediates endothelial injury during dialysis, but also compounds
endothelial damage caused by HD-induced ischemia and may induce a functional change in the
microvasculature. This assertion is supported by detection of strong negative correlations between
percent change in syndecan-1 and mean arterial pressure and between percent change in syndecan1 and microvascular perfusion.
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5.1.3 A Pilot Study: Assessment of intradialytic exercise on the circulation
and function of the heart
Recurrent myocardial injury due to hemodialysis can eventually lead to heart failure and
death. Injury has been attributed primarily to HD-associated circulatory stress and volatile
hemodynamics during HD. In a single HD treatment session, patients can experience episodic
hypotension and multiorgan ischemia. There have been studies of various interventions to improve
the hemodynamic tolerability of dialysis, including the use of a biofeedback dialysis system,
applying cooled dialysate, and prescribing remote ischemic preconditioning to a limb prior to HD.
However, one of the simplest and easiest to implement may be intradialytic exercise.
In Chapter 4, intradialytic exercise was studied as an intervention to mitigate HD-induced
cardiac ischemic injury. In particular, the aim of the study was to investigate the effects of
intradialytic exercise on the microcirculation and myocardial perfusion. Participants were asked
to engage in exercise during HD; their cardiac responses were evaluated with CT imaging and
echocardiography, while their microcirculation was assessed with plasma syndecan-1 levels.
Exercise did not affect myocardial perfusion during HD, with perfusion of the myocardium
reduced at peak HD (defined as three-hours into HD at the time of maximal circulatory stress) in
concert with a reduction in systolic blood pressure, regardless of whether exercise was performed
or not. However, exercise had a positive effect on the contractile function of the heart (as measured
using echocardiography) which improved with exercise intervention during dialysis. Intradialytic
exercise also caused an increase in plasma syndecan-1 levels.
Together, this suggests that intradialytic exercise may be cardioprotective by improving
cardiac contractility during dialysis without affecting myocardial perfusion, at the cost of acute
endothelial damage.
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5.2 Significance and Impact
The work completed in this thesis generated new understanding about the acute effects of
HD on the circulation, an area of nephrology that remains poorly understood. Utilizing state of the
art tools such as myocardial CT perfusion imaging and echocardiography intradialytically, the
detrimental effect of HD on myocardial segments in HD patients with coronary artery disease, a
rarely studied patient population, was demonstrated. Using an innovative small-animal
hemodialysis system, a preclinical dialysis research platform was developed that enabled the
observation of HD-induced microvascular dysfunction with intravital microscopy and plasma
syndecan-1 levels. Having established that both perfusion-related ischemic injury and systemic
microvascular injury occurs acutely due to hemodialysis, intradialytic exercise was evaluated as
an intervention for cardio protection against the acute effects of HD treatment. These contributions
are clinically impactful and have the potential to change our understanding of hemodialysis, to
change clinical practice, and to improve patient outcome.

5.3 Future Directions
5.3.1 A Comprehensive Study of the Coronary Arteries in HD
In Chapter 2 of this thesis, we have demonstrated that clinically significant coronary artery
stenosis aggravates HD-induced injury to the myocardium at a segmental level, with consequences
for the contractile function of the heart. This result was clear, despite having only three HD
participants with significant coronary artery stenosis and ten HD participants without coronary
artery stenosis. Coronary artery disease increases the harms of HD and increased understanding of
the effects of HD in the understudied population of patients with coronary artery disease on dialysis
is a must. To establish generalizability of these findings, a more comprehensive study with a larger
sample size would be valuable. In this larger study, nuances surrounding how coronary artery
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disease modulates the harms of HD can be established by assessing which coronary vessels are
stenosed, grading the degree and level of vessel stenoses, and relating this to segmental
measurements of segmental myocardial perfusion and contractility.

5.3.2 Sodium Induced Microvascular Injury with HD in an Animal Model of
CKD
In Chapter 3 of this thesis, an innovative small animal dialysis system was described and
served as the basis for a novel preclinical dialysis research platform. This platform enabled the
study of the effects of dialysate sodium on the microcirculation. A higher dialysate sodium caused
an increase in plasma sodium that resulted in direct injury to the endothelial glycocalyx, inducing
microvascular dysfunction during HD in healthy rats. In other words, the study described in
Chapter 3 established that large osmotic shifts during HD was detrimental to microvascular
function.
A more nuanced understanding around the degree of osmotic shift would be helpful. Using
the same preclinical dialysis platform, the effect of a wider range of dialysate sodium levels in
smaller increments of 2-4 mM on the microcirculation could be assessed, and a dose-response
curve generated. We could then establish whether or not there is a threshold at which osmotic
shifts become detrimental. Nuanced understanding around the rate of osmotic shift would also be
helpful. It is possible that a rapid dialysis rate causing a more rapid shift would result in greater
harm to the microcirculation. This understanding could be used to guide human studies in the
future with the ultimate goal of optimizing dialysis prescriptions to minimize circulatory harm.
Translatability of the results would be improved if rats with kidney disease were studied
rather than healthy rats, as was done in Chapter 3. It is logical to assume that circulatory response
to changes in sodium level during HD may differ depending on the level of kidney function.
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Although this can be directly studied in humans, extending the preclinical dialysis research
platform by creating and validating a reliable small-animal model of chronic kidney disease would
be valuable.

5.3.3 Optimization of Intradialytic Exercise
In Chapter 4, intradialytic exercise was assessed as a means of cardioprotection against the
acute effects of HD on myocardial perfusion and cardiac contractility. Although the literature has
established that different amounts of intradialytic exercise is comparable in terms of benefits, there
is no consensus regarding the optimal timing of exercise during HD for the most effective
cardioprotection. A randomized control trial with multiple arms corresponding to the timing of
intradialytic exercise (e.g. at the start of HD, 30 mins into HD, 1 hr, 1.5 hr, 2 h, and 2.5 hr from
the start of HD treatment session) would be needed to identify the golden time window at which
cardioprotection is maximized. Outcome measures can include the same measurements made in
the study described in Chapter 2 and 4. These include global and segmental myocardial perfusion
as assessed by intradialytic CT, as well as echocardiography to measure myocardial contractile
function at a segmental level.

5.3.4 HD-Induced Perfusion Anomalies and its Association with Clinically
Significant Cardiovascular Events
In the studies presented in this thesis, the detrimental effect of HD on myocardial perfusion
was well established. This effect was demonstrated over one dialysis sessions, but patients with
end stage renal disease require repeated dialysis treatment, often multiple times per week. This
results in recurrent cardiac ischemic injury. Recurrent cardiac ischemic injury is thought to be a
precursor to the development of clinically significant arrhythmia with the risk of sudden cardiac
death in this patient population. It would be important to establish how the altered myocardial

176

perfusion in HD relates to the development of clinically significant arrhythmia in future studies.
Possible mechanisms that may contribute include the disruption of the propagation of electrical
waves through ischemic zones and ectopic depolarization within injured myocardial regions. The
relationship between perfusion and arrhythmic events in the HD population is a missing piece of
our understanding that must be addressed.
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